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ABSTRACT 
 
 
 
The membrane bilayer delimits the interior of individual cells and provides them with 
the ability to survive and function properly. However, the crossing of cellular 
membranes constitutes the principal impediment to gaining entry into cells, and  
the potential therapeutic application of many drugs is predominantly dependent  
on the development of delivery tools that should take the drug to target cells 
selectively and efficiently with only minimal toxicity. Cell-penetrating peptides (CPPs) 
act in this context mediating the delivery of various cargoes such as nucleic acids, 
polymers, liposomes, nanoparticles and low molecular weight drugs. with low 
cytotoxicity and no restriction with respect to the size or type of cargo.  
Among these, peptide gH625 (HGLASTLTRWAHYNALIRAF), was previously 
identified as a membrane-perturbing domain in the glycoprotein H (gH) of the  
Herpes simplex virus type I. gH625 peptide interacts with biological membranes, 
contributing to the merging of the viral envelope and the cellular membrane; it is able 
to traverse the membrane bilayer and to carry cargoes like quantum dots and 100 nm 
polystyrene NPs inside the cytoplasm in an efficient way. In this context, the aim of 
this work is to investigate the ability of the gH625 peptide in the construction of novel 
materials, changing the classical intracellular fate of endocytic pathway and mediating 
the lysosomal escape of NPs made.  
Therefore, firstly, we focus on the combined effects of gH625 peptide and reverse 
transfection to develop a gene delivery platform based on functionalized 
polyethylenimine (PEI)/DNA polyplexes. We created PEI based polyplexes in which 
the gH625 was covalently coupled to 25 kDa PEI through a heterobifunctional 
polyethylenglycol (PEG) spacer. The obtained polyplexes were tested both in direct 
and reverse transfection approach, analyzing the cellular behavior in viability and 
x 
transfection efficiency assays. Results demonstrate that gH625 CPP functionalization 
allowed to increase the transfection efficiency of non-viral polymeric carriers,  
to reduce their own cytotoxicity and mediate an efficient gene transfer with respect to 
un-functionalized vectors. 
In the second part of the work we analyzed the role of particle size in influencing the 
ability of the gH625 membranotropic peptide to escape the endo-lysosomal pathway 
and deliver the particles in the cytosol. To this aim, we carried out a systematic 
assessment of cellular uptake and distribution of monodisperse platinum nanoparticles 
(PtNPs), having different diameters (2.5, 5 and 20 nm) and citrate capping or gH625 
peptide functionalization. Combining the enhanced uptake and partial cytosolic 
delivery promoted by gH625, we were able to achieve a strong improvement of the 
antioxidant nanozyme function of 2.5 nm PtNPs, decreasing both the endogenous  
ROS level and its overproduction following an external oxidative insult.  
Finally, in the last chapter, we analyze the behavior of gH625 in dual-functionalized 
polymeric carrier systems for targeted drug delivery across the blood-brain barrier 
(BBB), that represent the main obstacle in the treatment of Central-Nervous-System 
(CNS) diseases. The efficacy of NP functionalized with CRT and gH625 in promoting 
the translocation across the cerebral endothelium was assessed. Results from  
co-localization studies, adhesion and permeation assays across in vitro brain 
endothelial model under dynamic conditions establish that the cooperative effect  
of CRT and gH625 on NPs may change the distribution of NP in the cell and 
strengthen the BBB crossing of NPs. 
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Chapter 1  
 
 
Introduction 
 
 
 
Abstract: Cell-penetrating peptides are short and basic peptides, widely used due to their 
ability to deliver a cargo across the cell membrane both in vitro and in vivo. Here we report 
a general overview about many classes of CPPs, starting from their uptake mechanism, the 
intracellular trafficking and exploring their uses for many therapeutic applications. In this 
extensive scenario, a fascinating novel hypothesis is represented by gH625 
membranotropic peptides. It can efficiently cross biological membranes (including the 
blood-brain barrier), via local and temporary destabilization and reorganization of the 
membrane bilayer, and may also be able to enter cells avoiding the endosomal entrapment; 
in particular, by direct translocation or endosomal escape mechanisms. The role of this 
sequence is widely described in order to lead the reader through the many applications that 
are now emerging for this peptide. 
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1.1 Cell-Penetrating Peptides (CPPs) 
The hydrophobic nature of phospholipids membrane bilayer represent a selectively 
permeable barrier of living cells and protects them from the influx of exogenous 
molecules, including bioactive compounds such as peptides, proteins and oligonucleotides. 
In order to transport important molecules such as sugars and amino acids across the lipid 
bilayer, cells use a combination of channels and carrier proteins. Moreover, endocytosis or 
exocytosis mechanisms are used to transport material in bulk across the membrane.  
An accurate control of transport is generally helpful for the cell, but then many potential 
therapeutic drug targets become inaccessible. Thus, cells require entry of drugs in order to 
be effectively treated. While large macromolecular drugs, such as proteins or nucleic acids, 
are transported into target cells through both receptor-mediated or non-specific 
endocytosis, many small therapeutics are believed to go through a combination of  
carrier-mediated transport and passive diffusion.1 Regardless of the controversial opinions 
on which is the predominant mechanism,2-3cell entry remains a focus for those working in 
drug design and discovery. 
Several strategies have been developed to deliver therapeutic agents across cellular 
membranes such as microinjection, electroporation, liposome and viral based vectors. 
However, these methods have shown several drawbacks, including low efficiency, high 
toxicity, penurious bioavailability and poor specificity. An alternative strategy to overcome 
the impermeable phospholipid bilayer of the cell membrane emerged in latest ‘80s, from 
two different discoveries. Around the same time, first the HIV TAT transactivating 
factor,4-5 and then the Drosophila Antennapedia transcription factor proteins (later named 
penetratin)6 were shown to be able to translocate the cell membranes and enter the cells. 
After these parallel discoveries, it was demonstrated that short sequences of these proteins 
exhibited membrane-crossing properties. Thus, TAT and penetratin become the progenitor 
of a new type of molecular vector able to promote the delivery of a variety of cargoes:  
the cell-penetrating peptides (CPPs). 
In general, CPPs are defined as short, water-soluble and partly hydrophobic and/or 
polybasic peptides (from 5 up to 30-35 amino acids residues) with a net positive charge at 
physiological pH.7 The main feature of CPPs is that they are able to penetrate the cell 
membrane at low concentrations both in vivo and in vitro without using any chiral 
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receptors and without causing significant membrane damage. In addition, and even more 
important, these peptides are capable of internalizing electrostatically or covalently bound 
biologically active cargoes such as nucleic acids, polymers, liposomes, nanoparticles and 
low molecular weight drugs.8 Further characteristics of the CPPs are low cytotoxicity, their 
ability to be taken up by a variety of cell types, dose-dependent efficiency and no 
restriction with respect to the size or type of cargo.9 
In recent years the number of peptides identified as having cell-penetrating properties have 
expanded exponentially because they represent a promising tool for biomedical 
applications. The increasing interest of the scientific community about CPPs topic is due 
not only for their high internalization ability but also for the potential in variable 
modification design. 
 
Figure 1.1. Histogram showing the increase in publications related to the keywords "cell-penetrating peptide" 
during the past 50 years. PubMed data. 
1.2 Classification of CPPs 
As regards the classification of CPPs, there are several possible approaches. For example, 
CPPs can be subdivided into different classes based on their origin or sequence 
characteristics10 or otherwise by secondary structure or even their mechanisms of action. 
However, a major requirement for most of CPPs is the positively charged sequences of 
amino acids at physiological pH (primarily arginine and lysine) for the resulting 
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electrostatic interactions with negatively charged cell surface glycoproteins (before 
internalization).11At physiological pH condition, the guanidine head group of arginine can 
form hydrogen bonds with the negatively charged phosphates and sulfates on the cell 
membrane surface and may possibly lead to internalization process. The side chain of the 
amino acid lysine displays the same net positive charge as arginine, but the absence of the 
guanidine group results in a less effective penetration of the plasma membrane when acting 
alone. Consequently, the number and order of amino acids in the peptide sequence, 
especially arginines, is critical for determining the transduction properties of the CPP.12 
The membranolytic properties of a given CPP can also be governed by its secondary 
structure, specifically helicity. Indeed, it has been shown that peptides with an α-helical 
region can more efficiently enter the cells.8 
Although CPPs have a great sequence assortment, they can be generally divided into three 
other classes defined by their physical-chemical properties like peptide sequences and 
binding properties to the lipids.13 These classes include cationic, amphipathic and 
hydrophobic sequences.14-15 
Table 1.1. Representative cell-penetrating peptides: sequence, origin and function/application. Adapted with 
permission of Ref. 14 Copyright © 2013 Published by Elsevier B.V. 
CPPs Sequence Origin Function or application 
Cationic 
R6H4 RRRRRRH HHH Designed pH-sensitive delivery 
Penetratin RQIKIWFQNRRMKWKK Antennapedia 
homeodomain 
Targeted to human fibroblasts 
(RXR)4 (R-Ahx8-R)4 Designed Targeted to rpoD gene 
R9 RRRRRRRRR Designed Imaging and therapeutic agents 
delivery 
NLS CGYGPKKKRKVGG SV40 NLS peptide Nuclear localization 
 PKKKRKV Simian SV40 large tumor 
antigen 
Nuclear localization 
KAFAK KAFAKLAARLYRKALARQLGVAA Designed Anti-inflammatory 
hCT(9–32) LGTYTQDFNKFHTFPQTAIGVGAP A hormone secreted by the 
C cells of the thyroid 
Treatment of diseases, such as 
hypercalcemia or osteoporosis 
TAT YGRKKRRQRRR HIV-TAT domain Intracellular delivery of peptide-
blockers 
DPV3 RKKRRRESRKKRRRES Human heparin binding 
proteins and/or anti-DNA 
antibodies 
Specific subcellular delivery of 
therapeutic biomolecules 
Amphipathic 
RGD GRGDSY Various circulating 
proteins 
Integrin receptors targeting 
Sweet arrow 
peptide (SAP) 
(VRLPPP)3 N-terminal domain of 
Ȗ-zein 
Protease-resistance 
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hLF KCFQWQRNMRKVRGPPVSCIKR Antimicrobial peptides Antifungal, antimicrobial and 
antiviral activities 
MPG GALFLGWLGAAGSTMGAPKKKR
KV 
HIV glycoprotein 41 
protein 
Nucleic acids delivery 
pVEC LLIILRRRIRKQAHAHSK Murine vascular 
endothelial-cadherin 
protein 
Antimicrobial activity 
ARF(1–22) MVRRFLVTLR IRRACGPPRVRV p14ARF protein Induce cell apoptosis 
BPrPp (1–28) MVKSKIGSWILVLFVAMWSDVGL
CKKRP 
The N-terminus of the 
unprocessed bovine prion 
protein 
Transport the cargo across the 
endosomal membrane and into 
the cytosol and nucleus 
Bac7 RRIRPRPPRLPRPRPRPLPFPRPG Bactenecin family of 
antimicrobial peptides 
Antimicrobial activity 
MAP KLALKLALKALKAALKLA Chimeric Intracellular delivery of polar 
bioactive compounds 
DPRSFL DPRSFL Proteinase activated 
receptor 1 (PAR-1) 
Imaging 
VP22 NAATATRGRSAASRPTQRPRAPAR
SASRPRRPVQ 
Herpes simplex virus 
(HSV) 
Nuclear localization 
vT5 DPKGDPKGVTVTVTVTVTGKGDP
KPD 
Viral proteins Oligonucleotide and oligopeptide 
delivery 
C105Y CSIPPEVKFNKPFVYLI aa 359-374 of 1-antitrypsin Enhanced gene expression 
CADY GLWRALWRLLRSLWRLLWRA Designed Targeted siRNA delivery 
Pep-1 KETWWETWWTEWSQPKKRKV A tryptophan-rich cluster Nucleic acids and peptides 
delivery 
p28 LSTAADMQGVVTDGMASGLDKD
YLKPDD 
Azurin Antiproliferative and 
proapoptotic activity 
Hydrophobic 
PFV PFVYLI C105Y Deliver peptides into cells 
SG3 RLSGMNEVLSFRWL A randomized peptide 
library 
Gene delivery 
Pep-7 SDLWEMMMVSLACQY CHL8 Nucleic acids and peptides 
delivery 
FGF PIEVCMYREP Cellular and viral proteins Inhibition radiation induced 
apoptosis 
1.2.1 Cationic CPPs 
Cationic peptides represent the largest class of CPPs. They are characterized by the 
presence of a high positive net charge and few acidic amino acid residues. Studies suggest 
that at least eight positive charges are needed for efficient uptake of several cationic 
CPPs.16 Because of these electrostatic interactions with negatively charged glycoproteins 
on the cellular surface, they display a great potential as transmembrane carriers for 
therapeutic compounds.17 Cationic CPPs, since TAT (the best-known member of this class) 
was discovered, were originally considered as ‘Trojan horse’ delivery vehicles that enter 
the cells without causing a cellular response.18 On the other hand, cationic CPPs can induce 
a wide range of side effects, including consequences on membrane integrity and cell 
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viability, which might be less aggressive than cell death. Typically, R9,19 pTAT,20 hLF,21 
(RXR)422 and nuclear localization sequences (NLSs) also belong to this class. 
1.2.2 Amphipathic CPPs 
The term amphipathicity generally refers to molecules with both hydrophilic and 
hydrophobic faces.23 Peptides can be amphipathic in their primary or secondary structure. 
Peptides, such as MPG,24penetratin25 and CADY26 which contain both polar and nonpolar 
regions are defined as amphipathic peptides, based on their primary structure.  
Other primary amphipathic peptides, defined as chimeric peptides, correspond to the 
sequential assembly of hydrophobic and hydrophilic domains divided by a certain number 
of residues that acts as spacer. Chimeric peptides are also obtained by covalently  
attaching a NLS to a cell membrane targeting domain. For example, MPG 
(GALFLGWLGAAGSTM-GAPKKKRKV) is based on the SV40-NLS PKKRKV and the 
hydrophobic domain derived from the fusion sequence of the HIV glycoprotein 41, 
separated from the NLS through a linker (WSQP). Several other primary  
amphipathic CPPs are fully derived from natural proteins, such as pVEC,27 ARF (1–22)28 
and BPrPr (1-28).29 
Secondary amphipathic peptides are generated by the conformational state which allows 
positioning of hydrophobic and hydrophilic residues on opposite sides of the same 
molecule.30 Amphipathic α-helical CPPs have a highly hydrophobic patch on one  
face, whereas the other face can be cationic, anionic, or polar. The amphipathicity of  
ȕ-sheet structures are due one hydrophobic and one hydrophilic stretch of amino  
acids exposed to the solvent, such as vT5.31 In most cases, this structural organization  
of the amino acid residues occurs upon interaction with the phospholipid 
membrane, facilitating the peptide interaction and insertion into the bilayer.32  
Conformational polymorphism also plays a key role: in fact, the ability to shift  
from random to α/ȕ conformations as a consequence of membrane composition  
and peptide concentration has emerged as a common structural pattern for this  
class of peptides.32 
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1.2.3 Hydrophobic CPPs 
Hydrophobic peptides mostly contain apolar residues; they include stapled peptides,33 
prenylated peptides34 and pepducins.35 So far, only a few hydrophobic CPP sequences have 
been discovered, such as the signal sequences from integrin ȕγ (VTVLALGALAGVGVG) 
and Kaposi fibroblast growth factor (AAVALLPAVLLALLAP).36 Hydrophobic amino 
acids are also present in amphipathic CPPs, for example MAP,37 and in other longer 
chimeric CPPs, together with additional cationic residues for enhancing uptake and 
delivery capacity.38 
1.2.4 Other CPPs subgroups 
In addition to this ‘bulky’ CPP classification, additional CPP subgroups should be 
mentioned. A particularly interesting class of CPPs is proline-rich and poly-proline 
amphipathic sequences, which have been reported in diverse families that differ in 
sequence and structure. However, they all contain a proline pyrrolidine template.39  
Among all, the permeation ability of the sweet arrow peptide (SAP), which is a sequence 
with 50% proline content in addition to three arginine residues that is derived from a 
storage protein in maize, has been reported.40 
Even if proline has a hydrophobic nature, proline-rich peptides are unexpectedly soluble in 
water as well as a broad range of organic solvents. Ȗ-Amino-L-proline has an extra amino 
group (in the Ȗ position of the proline) that allows even higher water solubility. Thanks to 
the use of two orthogonal protecting groups for both the amino functionalities, the Ȗ-amino 
group is used in the peptide bond formation while the α-amino group may be properly 
functionalized in a following step. Therefore, Ȗ-amino-L-proline has been used as a very 
convenient building block for the preparation of cell-penetrating Ȗ-peptides, which can be 
considered special amphipathic peptides as a result of their backbone and their charged 
side chain linkages.41-42 
As more CPPs emerged, synthetic peptides have been developed using prediction 
programs, rational design strategies, or even trial and error procedures. In addition, 
research groups started to include non-primary and even unnatural amino acids41  
and other modifications in order to create new CPPs or improve existing ones.  
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For instance, substitution of a lysine residue with an ornithine residue leads to a better 
peptide resistance to cellular degradation.43-44 The peptide degradation prevention, with 
consequent increase of cargo delivery efficiency, can also be improved by changing the 
structure of the peptide itself (e.g. dendrimers45-51 or cyclic peptides52). 
Finally, antimicrobial peptides (AMPs) share molecular similarities with CPPs; they are 
cationic and may serve as potential structures for future drug delivery systems.40  
These antimicrobial peptides, such as LL-37, S413-PV and Buforin 2, are able to damage 
bacterial membranes during cell entry and possess microbicidal properties.  
1.3 Cellular internalization mechanisms of CPPs 
From the beginning there has been considerable interest in investigate how CPPs penetrate 
the cells. Although numerous studies about the uptake mechanism of CPPs across the 
plasma membrane have been reported, the pathways through which CPPs enter the cells 
have not been absolutely resolved yet.53 
CPPs are translocated into cells by several independent mechanisms but that can occur 
simultaneously. While direct translocation across the cell membrane occurs in some cases, 
it is generally accepted that the majority of CPPs and CPP-cargo complexes enter cells 
through an endocytic pathway.54 
The protein or peptide from which CPPs derive can often provide information about the 
mechanism of internalization. Mainly short, positively charged, arginine-rich CPPs interact 
with the negatively charged lipid membrane and activate permeabilization of the cell 
membrane through a receptor independent pathway, which results in endocytosis of the 
cargo, including macropinocytosis, clathrin mediated endocytosis and caveolae/lipid raft-
mediated endocytosis.55 
On the other hand, CPPs can cross the membranes through an energy-independent way 
known as the direct translocation pathway. In this case a spontaneous peptide-membrane 
interaction occurs and a translocation mechanism happens involving direct membrane 
penetration. This interaction is explained through different mechanisms such as the 
inverted micelle formation, pore formation, the carpet-like model and the membrane-
thinning model.13, 56-57 
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Figure 1.2. Mechanisms of cell-penetrating peptide uptake across the cellular membrane. They include 
endocytic energy-dependent pathways, based on vesicle formation, and direct translocation or cell penetration 
models, involving the formation of hydrophilic pores or achieving local destabilization of the lipid bilayer. 
Adapted with permission from Ref. 57. 
1.3.1 Direct translocation through the membrane bilayer 
All of the hypothesized direct translocation mechanisms can be clustered into four 
pathways (Figure 1.2):57 (i) inverted micelle formation,54 (ii) pore formation,58 (iii) the 
carpet-like model59 and (iv) the membrane thinning model.60 All these routes start with the 
interaction between the positively charged CPP and the negatively charged components of 
membrane such as the phospholipid bilayer as well as the heparan sulfate (HS).  
This interaction causes the folding of the peptide into the membrane with a subsequent 
destabilization of the lipid membrane.61-62 Generally, high CPP concentrations and primary 
amphipathic CPPs lead to a direct penetration following an internalization mechanism that 
depends on the peptide concentration, peptide sequence and lipid composition in each 
model membrane study.63-65 
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The “inverted micelle” is a suggested model for the direct penetration of penetratin.66  
It is characterized by an additional interaction between hydrophobic peptide residues and 
the hydrophobic part of the membrane. Thus, this mechanism is not probable for the highly 
cationic CPPs, such as TAT. 
Pore formation can be described by the barrel stave model and the toroidal model.57-58 
In the first one, helical CPPs form a barrel by which hydrophobic residues are close to the 
lipid chains and hydrophilic residues form the central pore. In the toroidal model, lipids 
bend in a way that the CPP is always close to the head group and both CPP and lipids form 
a pore. Both mechanisms depend on the overcoming of a certain peptide concentration 
threshold, which is different for different peptides. 
Lastly, in the carpet-like model59 and membrane thinning model,60 interactions between 
phospholipids and CPPs result in a carpeting and thinning of the membrane, respectively. 
Also in this case, translocation of the CPP is achieved when CPP concentration is above a 
limit value. 
1.3.2 Endocytosis-mediate uptake 
Endocytosis is a natural, energy-dependent, cellular process that starts with electrostatic 
interactions with proteoglycans at the cellular surface or by direct destabilization 
interactions across the lipid bilayer.56 Endocytosis of CPPs or CPP-cargoes (Figure 1.2) 
includes several pathways: phagocytosis for the uptake of large particles and pinocytosis 
for solute uptake. Pinocytosis is categorized as macropinocytosis and clathrin or caveolin 
dependent (or independent) endocytosis.67-68 
Macropinocytosis is associated with the inward folding of the outer surface of the plasma 
membrane, which results in the formation of vesicles called macropinosomes. Dynamin 
protein is required for membrane invagination. The resulting macropinosomes are 
surrounded by a membrane similar to the cell membrane.  
In receptor-mediated endocytosis, clathrin or caveolin are involved in the mechanism of 
uptake. They are required for invagination of the membrane and help to form the vesicles 
after the extracellular molecule binding to the membrane receptor.67-68 
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1.3.3 Significant factors that influence the mechanism of CPP uptake 
As mentioned above, the mechanisms of CPPs entries into cells have not been entirely 
clarified yet.69 Despite the similarities among CPPs, the mechanisms of their uptake 
considerably may vary due to several factors. The most important issue is represented by 
the CPP concentration as it can lead the activation of different uptake pathways.24, 70  
At low CPP concentrations, endocytosis is believed to be the main common uptake 
mechanism. Indeed, for many cationic CPPs, rapid cytosolic uptake is observed above a 
concentration threshold, which leads to direct translocation, while at lower concentrations 
the uptake is primarily endocytic.71-72 However, for primary hydrophobic CPPs at high 
concentrations, direct penetration is more probable. 
The concentration threshold for direct penetration differs among different CPPs, cell lines 
and the type and the size of the cargo. TAT attached to a large cargo is mostly entrapped in 
the endosomal vesicles; however, it redistributes throughout the cell cytosol or even deeper 
into the nucleus when attached to a small one.73-74 Furthermore, labeling a peptide with 
different fluorophores may also influence the uptake mechanism, intracellular distribution 
and cytotoxicity of the peptide.75-76 Other important experimental factors for the uptake 
mechanisms are, for example, cell type, temperature and incubation time. 
Despite all the debates about the route of entry, some consensual features are now 
privileged, hoping that further work could clear the variables affecting the modes of 
internalization. 
1.4 Uptake pathways and endosomal escape mechanisms of CPPs and 
CPP-Cargo complexes 
While the mechanism of CPP-mediated cell entry has been the subject of many studies, 
more work is needed to provide clarifications about the mechanisms of cellular uptake and 
internalization pathways of CPP-cargo complexes.53, 77 
The entry of a CPP-cargo complex into the cell could be influenced by several factors, 
including the physicochemical properties of CPPs (such as molecule length, charge 
delocalization, hydrophobicity), the nature of the attached cargo (type, size, surface 
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potential), differences in the cell line being utilized and the concentration of CPP. 
Depending on the size of the cargo, several internalization routes may act 
simultaneously. 
Generally, most cell-penetrating peptides or CPP-cargoes are taken up through 
endocytosis processes and they are immediately transported into the endocytic vesicles. 
Initially, the pH value in early endosome drops from neutral to around pH 6.44 
Then, early endosomes can follow two different pathways: (i) they may fuse with sorting 
endosomes and the internalized content can be transported out of the cell by exocytosis. 
More often, (ii) the delivery systems are trafficked to late endosomes which are rapidly 
acidified to pH 5-6 by the action of the ATPase proton-pump. Subsequently, the fusion 
with lysosomes (which contains various degradative enzymes) causes a further pH 
reduction to approximately pH 4.5 that facilitates substrate denaturation and helps 
lysosomal hydrolases, most of which operate optimally in the range of pH 4.5-5.5.78 
 
Figure 1.3. Schematic representation of the intracellular trafficking mechanisms. CPPs and/or CPP-cargoes are 
able to reach cytoplasm through a direct translocation mechanisms across cell membrane (route 2), or, when 
endocytosis takes place, via endosomal escape (route 1). The ability of CPPs to avoid accumulation into 
lysosomes is strictly related with the reduction of cytotoxicity. Adapted by permission from Ref 79 © 2015 IOP 
Publishing Ltd. 
CPP-cargoes that fail to be released from these acidic vesicles will ultimately be degraded. 
This accumulation leads to two important consequences: (i) a low efficiency for a 
successful delivery80-81 and (ii) an increase of NP toxicological effects due to the very 
degradative environment in the lysosomes.82-83 
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Ideal CPP-cargoes should be released from these acidic compartments at an early stage 
in order to explicate their function and prevent the fate of lysosomal destruction. 
Therefore, CPPs have a second chance to exemplify their function inducing 
endosomolytic activity and promote endosomal escape following the same direct 
membrane translocation mechanisms described above (1.3.1). Furthermore, during the 
acidification of the endosomes, the imidazole groups of histidine residues could also be 
protonated and the peptide increases its net positive charge, intensifying its interaction 
with the anionic lipids in the endosomal membrane. Thus, membrane destabilization 
occurs, followed by the release of the construct into the cytosol.84 
Pore formation is another mechanism that explains the endosomal escape of peptide-
based delivery systems. In addition, multiple mechanisms may be accounted for the 
enhancement of transfection efficiency, including structural changes of the peptide  at 
low pH values, facilitation of nucleic acid dissociation from the lipoplexes and the flip-
flop mechanism.85 
1.5 Biomedical and therapeutic applications of CPP 
There is now convincing evidence that CPPs have a therapeutic potential and, indeed,  
they have been efficaciously used to facilitate the intracellular delivery of several 
molecules of pharmacological interest in different cell lines. It has already been proven 
that they have the potential to improve intracellular delivery of a large arsenal of 
biologically active agents.86-88 Since their discovery, CPPs have been conjugated to 
cargoes with a large number of different sizes, transporting them both in in vitro and in 
vivo experiments. Cargo examples are peptides, proteins, nanoparticles, nucleic acids 
(oligonucleotides, cDNA, RNA, siRNA), fluorochromes, antibodies, lipid-based 
formulations, quantum dots, viruses, contrast agents for magnetic resonance imaging 
and drugs (Figure 1.4).10, 57, 87-89  
In this paragraph, some of the numerous instances where CPPs have been used to  
deliver therapeutics are highlighted. As concern in vivo delivery, many of the examples 
are limited to small animals and application of CPPs to human therapeutics has yet to 
prove effective. 
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Figure 1.4. Several applications of Cell-penetrating peptides as molecular delivery vehicles for a variety of 
drugs, nucleic acids, proteins, therapeutics, and imaging agents. Reprinted with permission of Ref. 10 Copyright 
© 2012 Elsevier Ltd. 
 
Nucleic acid delivery 
One of the first biomedical applications of CPPs was the delivery of nucleic acids into 
cells. Generally, plasmids DNA are not able to reach the cell nuclei because of both 
nuclease enzymatic degradation processes and inefficient capacity of passing through the 
cell membrane. To improve the delivery of nucleic acids, plasmid DNA has been 
complexed with cationic polymers, liposomes or cationic CPPs, which condense DNA into 
particles capable of entering the cells through endocytosis.90 
CPPs have been used also to functionalize existing synthetic gene vectors.  
For instance, polyarginine functionalized lipoplexes efficiently silenced genes in a  
mouse liver.91 Furthermore, an unexpected and interesting finding was that CPPs  
seem to be able to improve the long-term gene expression from vectors. For example, 
PEI coupling with TAT CPP extend the gene expression period from about 1 month  
to almost 7 months compared to TAT or PEI alone.92 
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Peptides, proteins and enzymes 
As with gene delivery, proteins are typically unable to passively enter the cells. CPPs make 
it possible to transport enzymes and other therapeutic targets, which can lead to treatments 
for a wide range of diseases. Enzymes that prevent oxidative damage, used for treatments 
against ischemic injury, are just one of several types of protein of interest for intracellular 
delivery. For example, TAT CPP was combined with glyoxalase to prevent oxidative 
damage of neuronal cells.93 Moreover, TAT was used to improve cell delivery of 
antioxidant enzymes catalase and superoxide dismutase, which protected the cells from 
oxidative stress.94-95 
Small molecules & cancer treatment 
Small hydrophilic molecules have difficulties in traversing the hydrophobic cell 
membrane. Additionally, diseases, such as cancer, can also preclude an effective transport 
of small molecules across the lipid bilayer and these kinds of drugs are sometimes toxic 
and expensive. Therefore, new strategies to develop modalities to cure cancer are needed. 
Anticancer drugs affect cell growth, vascularization and metastatic spread by preventing 
effective DNA replication, by damaging the mechanisms of cell division or by blocking 
the paths implicated in cell growth.96 Small chemotherapeutic drugs such as doxorubicin, 
methotrexate, cyclosporine A, paclitaxel, properly developed with CPPs, represent a very 
promising tool for the treatment of critical tissues such as tumors, heart, etc.97 Thanks to a 
better interaction with glycosaminoglycans, the cationic CPP polyarginine can drive 
doxorubicin to the inhibition of tumor growth in vivo with fewer side effects compared to 
doxorubicin alone.98 Moreover, doxorubicin was loaded in cancer cell by means of PFV 
CPP functionalized liposomes with significant reduction in tumor volume and fewer side 
effects compared to an unmodified liposome.99 
CPPs in imaging 
Imaging is a growing field in the detection and monitoring of disease markers, which can 
lead to a more effective disease management. CPPs have been coupled with contrast 
agents, fluorophores, quantum dots and other readily detectable molecules in order to 
improve their permeability53 and visualize the intracellular environment, as well as for 
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specific cells in a tissue. The high efficiency characteristic of CPPs makes them promising 
tools in the imaging field such as proteases detection,100-101 optical imaging of cancers102-103 
and molecular imaging analyses104 providing novel and powerful tools in the development 
of new imaging agents. 
CPPs with nuclear localization sequences (NLSs) to improve nuclear import efficiency 
To improve nuclear import efficiency, CPPs have been attached with nuclear localization 
sequences (NLSs) to DNA or gene carriers.105As mentioned in paragraph 1.2.1, NLSs are 
special cases of cationic CPPs, characterized by the presence of lysine-, arginine- or 
proline-rich motifs that can be recognized by members of the Importin super family of 
nuclear transport proteins. Thus, NLS promote the overcoming of the nuclear membrane 
barrier in nuclear translocation processes.106 The most extensively studied NLS sequence 
for gene therapy is derived from the large tumor antigen of the simian virus 40 (SV40).107 
CPPs-modified pH-sensitive delivery 
Acidic pH is another feature that influences the cytoplasmic delivery of cargo molecules 
performed with CPPs.19, 62, 73, 76, 108-109 Because of the pH gradient between the lysosomal or 
tumor milieu and the physiological environment, triggered exposure mechanisms of  
CPPs-cargo can be activated.  
Exposure mechanisms include acid-degradable cross-links,73, 76, 109 removal or enzyme 
degradation of protective coat21, 108 and so on. These selective deliveries through triggered 
work mechanisms enhance the therapeutic efficiency of nanocarriers and decrease toxicity. 
1.5.1 Exploiting the synergistic effects of targeting ligands and CPPs 
Cell-penetrating peptide (CPP)-based delivery systems represent a strategy that facilitates 
pharmaceutical import efficiently into cells110 In many cases, this approach occurs with 
some lack of specificity that implies lower efficacy and safety during the whole process. 
As a result, this issue is probably one of the major drawbacks for the use of CPPs as 
delivery vehicles in vivo.69 Novel approaches to improve the targeted delivery of 
biomolecules combined with CPPs, such as conjugation with targeting ligand in order to 
elicit cell surface binding and receptor-mediated endocytosis, have been developed. 
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In order to achieve a synergetic effect of targeting ligands and CPPs to improve  
cancer-cell selectivity, several research groups have focused the attention on the CPP-TPP 
(Tumor Targeting Peptide) conjugates in anticancer drug delivery for site specific transport 
of therapeutics. Conjugation of TTPs with CPPs facilitates the translocation of the 
conjugate unit to target tumor sites with enhanced specificity and selectivity.111  
Furthermore, modifying anticancer agents with CPPs, for example, conjugating a  
TAT-derived CPP with an anti-Her-2/neu peptide mimetic,112 AHNP, could selectively 
make this mimetic binds target to ErbB2, an epidermal growth factor receptor over-
expressed in 30% of breast cancers.113 
Synergistic effects of targeting ligands and CPPs can also be accomplished by employing a 
natural ligand (or a truncated version thereof) which can bind a receptor expressed on the 
target organ or tumor and penetrate cell membrane through endocytosis.114 Additionally, 
exploiting bioinformatic design of a peptide library solves crystal structures can identify 
potential ligands for receptor targets These approaches bypass the need for screening and 
synthetizing large peptide libraries.115 Moreover, direct targeting design can offer a good 
basis for the development of targeting tools.14 
1.5.2 Future prospects of CPPs 
It is without doubt that from their first serendipitous discovery to the present day, CPPs 
have opened many doors to a wealth of biomedical and therapeutic opportunities both in 
vitro and in vivo. However, many features are still a matter of debate and open several 
scenarios for the future CPPs developments. In vitro CPP tracking demonstrated that a 
single mechanism could not explain the intracellular pathway of CPPs.13  
Several differences in experimental conditions, for example the CPP concentration, the cell 
type, the conditions of incubation, the type and size of the cargo as well as the binding 
methodology, lead to the observation of contradictory results. There is still a major need to 
compare different CPP-mediated delivery systems in the same cell model. Recent attempts 
have been made to compare the effects of the cargo, but it is still impossible to define 
precise guidelines that might clarify all the observed divergences. 
Moreover, the lack of cell specificity of CPPs along with their weakness to proteolytic 
cleavage under physiological conditions has led to the design of so-called ‘smart’ delivery 
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platforms, exploiting peculiar physiological or micro-environmental features related to the 
targeted tissue or cell type. CPP-modified nanocarriers should be designed in such a way 
so that during the first phase of their delivery surface CPP moieties are sterically shielded. 
After reaching their target (passively or actively), CPPs should be exposed under unique 
local conditions to enhance a penetration of the carrier through the cell membrane followed 
by intracellular delivery of its bioactive cargo. With these perspective, cancer cells 
metabolism and additional pathological conditions can be used as triggers for CPP 
exposure for an effective intracellular drug delivery.10 Chemical modifications of the 
structure of known CPPs or logical design of novel CPPs represent also a new effective 
rationale that could improve CPPs efficiency as regards as specificity and resistance to 
proteolytic degradation in cellular environment.8 
Finally, the abundance of drug-discovery data and now a growing mass of in vivo 
applications, also considering the current inefficiency of traditional drug-discovery 
programs, require the use of CPP technologies as biomedical tools and molecular 
therapeutics further into drug development and clinical setting.116 
1.6 A case study: the gH625 cell-penetrating peptide 
The use and the study of the sequence “gH6β5” have been revolutionary in understanding 
the role of hydrophobic viral peptides. gH625 derives from glycoprotein H (gH) of  
Herpes simplex virus type I. Herpes simplex virus (HSV) is a well-known human pathogen 
with high range of worldwide morbidity and mortality and its complex multi-component 
entry technology has been widely studied because of its highest fusion capability. 
It is not yet well understood the role of the other membranotropic sequences, in particular 
by the glycoprotein H. Nevertheless, it is now widely accepted that several regions are 
involved in the local destabilization of the membrane bilayer which tops in the fusion of 
the viral envelope with the host cell membrane. 
gH625 was first selected and characterized in 2005,117 and was initially identified using the 
WWIH (Wimley-White interfacial hydrophobicity) scale. Following works allowed to 
determine the many uses of this sequence (thanks to its fusion capability), from membrane 
fusion to viral inhibition and drug delivery.118-120 
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1.6.1 General description and membrane interactions 
The twenty residue peptide gH625 (Figure 1.5 – HGLASTLTRWAHYNALIRAF – from 
aa 625 to aa 644) is rich in hydrophobic residues including glycines, leucines, alanines 
and aromatic residues like tryptophan and tyrosines, which are favorably located at the 
membrane interface. The peptide-lipid interactions starts with the action of the arginine 
residue (R18) located at the C-terminus, indeed the mutation of arginine strongly 
weakens the fusogenic properties of the peptide.121-124 
The hydrophobic domain is also critical for the insertion of the peptide into the 
membrane and supports the opinion that hydrophobic interactions between cell 
membrane phospholipids and fusion proteins initiate membrane perturbation at the 
initial stages of viral fusion. The numerous biophysical experiments made on gH625 
demonstrated that the peptide interacts with model membranes, enters the bilayer from 
its N-terminal side, has a tryptophan residue hidden inside the bilayer and adopts a 
helical conformation with its hydrophobic residues on one face of the helix and polar 
or charged residues on the opposite face (Figure 1.5 A).117, 122-123  
The analysis of peptides with longer and shorter sequences resultant from this  
region and of their interactions with membranes demonstrated that the activity of  
this region depends on the amino acid sequence and on its length. The histidine  
residue at the N-terminus of the native sequence is also responsible to the  
increase fusion activity, since it helps both the initial interactions with the  
membrane and the oligomerization process:122 this hypothesis is additionally  
supported by the fact that the histidine is placed at the N-terminus and the correct 
configuration of peptide appears to be crucial for the fusogenic function of several 
fusion proteins as well as its location in the membrane core after peptide-bilayer 
interaction. This histidine residue is sufficient to make the peptide approximatively  
8-fold more active.  
gH625 powerfully interacts and naturally penetrates the lipid-phase and inserts into 
membranes with a α-helical structure.122, 125-126 Both the tryptophan and tyrosine are on 
the same side of the helix in the three-dimensional structure forming an amphiphilic 
helix, which on one side is constituted by aromatic and hydrophobic residues and on 
the other one is formed by hydrophilic or small residues (Figure 1.5 B).  
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During the contact with the membrane the interaction between the aromatic ring  
of the tryptophan and the side chain of the tyrosine is fundamental for the structural 
stability. An amphipathic α-helix of membranotropic peptides play a crucial role  
for mediating lipid-protein interactions during the binding of proteins to membranes; 
once bound, the hydrophobic face of the amphipathic peptide would allow the  
peptide to enter the membrane interior triggering local fusion of the membrane  
leaflets, transient pore formation, cracks and membrane fusion.30 gH625 has the  
ability to penetrate deep into the bilayer as a helix without causing significant  
bilayer perturbations. This feature may help explaining its ability to perform various 
roles. 
 
Figure 1.5. (A) Helical wheel representation and (B) energy-minimized structure of the amphipathic α-helical 
model of the 20-mer gH625 peptide illustrate the amphiphilic character of gH625 peptide. All the hydrophobic 
residue side chain (yellow) fall on one face of the helix while the charged (blue) and the polar (violet) residues 
stays on the hydrophilic side of the helix. Adapted with permission of Ref. 125 © 2012 American Chemical 
Society. 
1.6.2 Drug delivery application 
The ability of gH625 to traverse the membrane bilayer has been recently validated,  
it also has the ability to transport several compounds into the cytosol, such as  
QDs,127-128 liposomes,129 NPs,130-132 dendrimers133 and proteins.134 Examples of  
using gH625 as an intracellular delivery enhancer are described as follow  
(Figure 1.6).135 
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Figure 1.6. Major applications of gH625 peptide to drug delivery. Confocal microscopy images showing the 
internalization of gH625 functionalized: (a) proteins;134 (b) liposomes;129 (c) Quantum dots;127 (d) 
dendrimers.133 (e) Scanning electron microscopy images of functionalized polystyrene nanoparticles.131 
Adapted with permission of Ref. 135 © 2014 Elsevier B.V. 
gH625-QD internalization was demonstrated to be highly successful and to implicate only 
to a minor degree the endocytic pathway.127 Liposomes with gH625 and loaded with 
doxorubicin129 were able to enter inside living HeLa cells; the results suggest that the 
functionalization of liposomes with gH625 could affect the uptake mechanism of 
liposomes and their intracellular distribution, and doxorubicin release. This information 
could be useful in the design of carriers for a controlled delivery and release of 
doxorubicin in order to avoid side effects associated to doxorubicin itself.  
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Dendrimers136-137 also represent a very powerful instrument for drug delivery, combining 
the ideal size as in vivo carriers and multivalency of nanoparticles, the low cost, the tunable 
properties and biocompatibility of polymeric materials plus the monodispersity and 
detailed control of small molecules.137-138 Their surface modification, by means of 
conjugation or adsorption of a biospecific ligand, may allow their delivery to specific sites 
and modulations of drug release minimizing toxic effects and increasing intracellular 
bioavailability.139 The attachment of gH625 to dendrimer allows the conjugate to enter into 
the cellular matrix, whereas the un-functionalized dendrimer is omitted from translocation. 
The peptide-functionalized dendrimer is rapidly taken into the cells mainly through a  
non-active translocation mechanism.133 The combination of the benefits of dendrimers and 
peptide chemistry could be useful for the development of a selective carrier, which could 
cross the membrane and be proficiently internalized into the cellular targets. 
1.6.3 Delivery across the blood-brain barrier 
The blood-brain barrier (BBB) protects the brain and excludes many therapeutic drugs 
from entering.140 Most of the strategies to transport drugs inside the central nervous 
system (CNS) cause disruption of the anatomical texture of the BBB, impairing its 
natural function; therefore, effective delivery approaches should be thoughtfully 
evaluated considering their effect on the function of the BBB.141-142 Targeted delivery of 
a therapeutic cargo appears to be one of the most auspicious non-invasive approaches to 
overcome the BBB, combining the advantages of brain targeting, high incorporation 
capacity, reduction of side effects and circumvention of the multidrug efflux system.143-
145 Polystyrene nanoparticles (NPs) decorated on their surface by gH625 showed that the 
uptake of NPs by brain endothelial cells was superior than that of the NPs without the 
peptide, functionalized NPs were also free to move intracellularly.131 Above all, gH625 
decreased NP intracellular accumulation as large aggregates and improved the NP-BBB 
crossing with low toxicity.79 
The ability of gH625 to cross the BBB in vivo was recently estimated.146 gH625 was 
administered in vivo to rats and its presence in the liver and in the brain was detected 
within 3.5 h in proximity of cell neurites. gH625 has no toxic effect in vivo, since it  
does not affect brain maximal oxidative capacity and mitochondrial respiration rate. 
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gH625 constructs represents an innovative nanocarrier system for drug delivery to the 
central nervous system for its ability to cross the BBB. These results open new 
possibilities for direct delivery of drugs and might address the treatment of several 
human diseases. 
gH625 is the first viral membranotropic peptide which can be used as delivery system for 
macromolecules in vivo; these results coupled with previous in vitro data support the 
view that gH625 enters the BBB without involving endocytic processes and damaging it. 
Hence, the eventual cargo may be immediately and completely available.146 The use of 
such peptide-based ligand for targeted drug delivery in vivo may be restricted by the 
presence of several metabolic barriers. gH625 starts to degrade after 1 h of incubation 
but the intact peptide is still present after 3.5 h of incubation and thus could extend the 
brain targeting efficiency.146 
1.7 Aim and Outline of the Thesis 
Intracellular delivery of potentially diagnostic or therapeutic molecules is one of the key 
problems in drug delivery because of the presence of the plasma membrane of cells. It 
represents an effective semi-permeable barrier that is essential to cell integrity and 
survival. Up to now, multiple and only partially successful attempts have been done to 
bring various drugs and drug-loaded pharmaceutical carriers directly into the cell 
cytoplasm bypassing the endocytic pathway, in order to protect cargoes from the 
lysosomal degradation. The discovery of cell-penetrating peptides (CPPs) launched a 
novel field in molecular delivery based on these non-invasive vectors. These peptides are 
able to cross cellular membranes and efficiently transport various biologically active 
molecules inside living cells and thus are considered promising devices for medical and 
biotechnological developments. Among this, gH625 CPP has shown exceptional vector 
properties In fact, it is able to efficiently deliver a range of cargoes also by a non-
endocytic pathway, avoiding endosomal entrapment producing the desired biochemical 
effect in the expected cellular localizations. 
At the moment, researchers are focusing on the enhancement of CPPs cell specificity and 
the exploitation of novel technical strategies for pharmaceutical development of viable 
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CPP-carriers for drug delivery and numerous other applications. For these reasons,  
in this work, different gH625-based materials were designed in order to exploit the  
CPP properties in many field of nanomedicine. Moreover, in each Chapter an  
original biological application is proposed, where gH625 functionalization show 
considerable advantages in increasing the overall nanomaterial performances, such as 
changing their classical intracellular fate of endocytic pathway and mediating lysosomal 
escape. Following, the outline of the thesis is reported with a brief description of  
each chapter. 
The Chapter 1 of this thesis presents an introduction on Cell-Penetrating Peptides  
with an overview of their classification, cellular interaction and applications in 
biomedical field. Then, an outline of the “gH6β5” CPP is exposed, highlighting  
the potential application of this peptide in nanomedicine. In Chapter 2 we focused on 
the combined effects of gH625 peptide and reverse transfection to develop a gene 
delivery platform based on functionalized polyethylenimine (PEI)/DNA polyplexes.  
We created a PEI based vector in which the gH625 was covalently coupled to 25 kDa 
PEI through a heterobifunctional polyethylenglycol (PEG) spacer. Transfection and cell 
viability assays were carried out using adsorbed or covalent bonded complexes on  
glass surface. In Chapter 3 we analyzed the role of particle size in influencing  
the ability of the gH625 membranotropic peptide to escape the endo-lysosomal  
pathway and deliver the particles in the cytosol. To this aim, we carried out a systematic 
assessment of cellular uptake and distribution of monodisperse platinum nanoparticles 
(PtNPs), having different diameters (2.5, 5 and 20 nm) and citrate capping or gH625 
peptide functionalization. 
Moreover, gH625 also demonstrated the ability to penetrate the Blood Brain Barrier 
(BBB) both in vitro and in vivo. In Chapter 4, this feature was exploited analyzing  
the behavior of gH625 in dual-functionalized polymeric carrier systems for targeted  
drug delivery across the BBB. The specificity of the nanomaterial in targeting the  
BBB is given by the peptide CRTIGPSVC (CRT), which functionally mimics  
the endogenous iron and promotes the crossing. Finally, in Chapter 5, a summary  
about the main results achieved in this thesis is presented and future applications are 
proposed.  
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Chapter 2  
 
 
Substrate-mediate gene delivery platform 
based on functionalized PEI/DNA polyplexes 
 
 
Abstract. In this study, we describe a new modification of PEI, in which the gH625  
cell-penetrating peptide was covalently coupled to 25 kDa PEI through a 
heterobifunctional polyethylenglycol (PEG) spacer resulting in a gH625-PEG-PEI 
conjugate. The new vector and the obtained polyplexes were widely characterized by  
1H-NMR spectroscopy and confocal and electronic microscopy, respectively. Furthermore, 
transfection efficiency and cytotoxicity of both PEI and gH625-PEG-PEI polyplexes with 
DNA were evaluated under in vitro conditions (NIH-3T3 cell line) using both direct and 
reverse transfection methodologies. In all cases, improved cell viability and DNA reporter 
gene complexation and delivery were observed for gH625-polyplexes. Finally, a new 
strategy to covalently bound functionalized polyplexes on a silanized glass substrate has 
been developed in order to explore the potential advantages coming from this technique. 
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1.1 Introduction 
Plasmid DNA complexation with vectors sustain the cell internalization and the 
transfection activity, although a high efficiency and duration of gene expression are not 
always guaranteed. Gene vectors can facilitate intracellular trafficking which includes 
endosomal escape, cytoplasmic transport, nuclear entry and the dissociation from the 
DNA to allow gene expression.1-2 In particular, non-viral vectors are safer and easier to 
prepare than viral vectors, but typically have lower efficiency and shorter duration of 
gene expression.3 Regarding the more traditional delivery methods, controlled delivery 
systems have the potential to overcome extracellular barriers, as well as enhance gene 
delivery.4 
In recent years, the development of systems capable of controlled and efficient gene 
transfer has been widely investigated in in vitro research and in diagnostic applications.5  
In particular, gene delivery from surfaces is the basis of many screening systems to 
examine the cell response to the altered gene expression within a more representative 
biological context.5-6 Cell-based array technology permits simultaneous detection of 
several different activities located at the surfaces or inside cells, allowing the complex 
characterization of cells with an amount of information that is hardly assessed by any 
other technique7 such as cell arrays for studies in functional genomics 8-10 or patterned 
gene delivery for models of tissue growth.11-12 
Substrate-mediated gene transfer, also known as reverse transfection, immobilizes the 
DNA to a substrate that supports cell adhesion, placing the vector directly in the cellular 
microenvironment, reducing mass transport limitations and localizes delivery. 4, 13-14  
The retention or release of DNA from surface can be dictated by the strength and 
specificity of the molecular interactions between the vector and substrate.15-17 
The immobilization of vectors provides many advantages as regards transfection 
efficiency, although a correct balance between the binding to the substrate and the 
vehicle release ability is necessary. 
Moreover, some other limiting factors have to be considered in non-viral gene delivery.  
(i) The concentration of DNA at the cell surface14 leads to mass transport issues such as 
aggregation effects in case of excessive high density of the complexes on substrate. 
(ii) The chemistry of substrate itself (size and shape) affects the immobilization and 
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expression of non-viral vectors. For instance, the inclusion of PEG-like moieties 
influence the surface properties of PEI polyplexes adsorbed to monolayers of carboxylic 
end groups, increasing their transfection efficiency.13 (iii) Non-viral gene vectors have to 
overcome a series of barriers to transport DNA from the cytoplasm to the nucleus.  
In particular, the accumulation in lysosome compartment decreases the transfection 
ability and causes cytotoxic effects due to the low pH and the degradative environment.18 
Generally, positively charged vectors entrapped in endosomes19 are able to escape  
via the “proton sponge effect,” in which the buffering capacity of the cationic  
polymer leads to an osmotic pressure increase when the endosomal pH drops,  
ultimately causing the endosome rupture and releasing the polyplexes into the cytosol.20 
However, this proton sponge effect is apparently not sufficient to release the majority  
of PEI particles from the vesicles, especially with small PEI polyplexes at low 
concentrations.21 
A promising approach to further increase cell uptake and endosomal escape of 
polyplexes is represented by the use of cell-penetrating peptides (CPPs), whose 
membranotropic action has been shown to significantly favor the uptake of a variety of 
molecules and cargoes even reducing their own cytotoxicity.22 For example, TAT-
derived PEI mediated cell uptake of DNA, increase DNA condensation and polyplex 
stability. Moreover, peptide functionalization significantly reduced the cytotoxicity and 
demonstrated higher transfection efficiency than PEI. 
As a matter of fact, in order to overcome the gene delivery limitation previously 
described, the aim of this study was to combine favorable characteristics of PEG-grafted 
PEI, cell-penetrating peptides and reverse transfection approach in order to create a 
substrate mediate gene delivery platform with functionalized vectors capable of 
mediating efficient transfection. In addition, the new vector should be able to mediate 
gene transfer and exhibit a lower toxicity with respect of PEI. Experimental model of the 
gene delivery platform is showed in Figure 2.1. 
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Figure 2.1. Experimental model of the covalently bonded gH625-PEG-PEI/DNA polyplexes on the substrate 
mediated gene-delivery platform. 
In this chapter we report the synthesis, characterization and cell transection behavior of 
polymer conjugates in which a CPP, namely gH625, modified by a C-terminal cysteine 
residue is covalently coupled to linear PEI (25 kDa) using a hetero-bifunctional PEG 
based linker. The peptide gH625 belongs to the glycoprotein H of Herpes simplex virus 
type I (HSV-1) and is a membranotropic domain which contributes to the fusing of the 
vires with the cell membranes.23-24 This peptide exhibit exceptional vector properties 
and has been shown to be principally internalized by a direct translocation mechanism, 
avoiding endosomal entrapment. Therefore, gH625 is a very good delivery vector and 
its coupling to nanocarriers may be exploited to change their internalization 
mechanism and to avoid or reduce their toxicity.25-32  
Additionally, immobilization of bioactive compounds on a surface can be used to 
extend its half-life and stability or prevent its metabolism. Besides the conventional 
adsorption method, the new approach developed in this work is based on a covalent 
attachment of polyplexes on a functionalized glass surface through PEG spacer. 
Tethering the complexes to a solid substrate via a spacer molecule can also improve 
bioactivity by reducing steric constraints and shielding them from surface induced 
denaturation. 
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1.2 Experimental section 
2.1.1 Materials  
Linear Polyethylenimine (L-PEI, av. MW 25 kDa) was purchased from Polysciences 
(Warrington, PA). Tetramethylrhodamine-conjugated linear PEI (JetPEI-fluoR) was 
purchased from Polyplus-transfection SA (7mM ammine content, Illkirch, France).  
All Fmoc-aminoacids and α-Succinimidyl ester-ω-propargylacetamido poly(ethylene 
glycol) (NHS-PEG-Alkyne, MW 3.3 kDa) were purchased from IRIS Biotech GmbH 
(Germany). 3-brompropyl trimetoxysilane (BPTMS), Sodium azide, 2-(N-
Morpholino)ethanesulfonic acid hemisodium salt (MES buffer), 1-ethyl-3(3-
dimethylamino-propyl)-carbodiimide hydrochloride (EDC), 2-Hydroxy-2-
methylpropiophenone (DAROCUR 1173), N-hydroxysuccinimide (NHS) Sodium 
ascorbate, Copper sulfate pentahydrate (CuSO4·5H2O), N,N-diisopropylethylamine 
(DIPEA), O-benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro-phosphate (HBTU), 
Ethyl (hydroxyimino)cyanoacetate (Oxyma Pure®), anhydrous N,N-dimethyl-formamide 
(DMF), Acetonitrile (ACN), Rhodamine B, Dichloromethane (DCM), Methanol, Ethanol, 
Acetone, Piperidine, Toluene, Trifluoroacetic acid (TFA), Triisopropylsilane (TIS), Acetic 
Anhydride, HPLC-grade water, 2,2,2-trifluoroethanol (TFE) and all buffer solutions were 
purchased from Sigma-Aldrich (USA). Hoechst 33342 trihydrochloride trihydrate was 
purchased from Invitrogen (USA). Dialysis bag MWCO 6000-8000 Da were purchased 
from Spectrum Laboratories, Inc. (Netherlands). Distilled and deionized water used 
Millipore Milli-RO 10 Plus (Millipore, USA) at 18 MΩ resistance. Amicon® Ultra-4 
centrifugal filters were purchased from Millipore Merck. 
2.1.2 Amplification and purification of plasmid DNA  
Plasmid DNA, pTagGFP2-actin (Evrogen, Russia), containing a reporter gene encoding for 
green fluorescent protein (GFP) (bright green fluorescence with ex/em maxima at 483 and 
506 nm, respectively), was used for fluorescent labeling of ȕ-actin intransfection studies. 
The chemically competent DH5αTM bacterial strain (Escherichia coli species) was 
transformed with pTagGFP2 using heat shock method. Plasmid DNA in the transformed 
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culture was then expanded in E. coli in Lennox L Broth (LB Broth) supplemented with 
50 mg/L kanamycin overnight at 37 °C in an incubator, shook at 300 rpm. Plasmid DNA 
was extracted and purified from bacterial culture using an Invitrogen PureLink™ HiPure 
plasmid filter midiprep kit according to the manufacturer’s specifications.  
The concentration (adjusted to 0.5 ȝg/ȝL) and the purity of plasmid DNA solution were 
determined using a UV-Vis Spectrophotometer by measuring the sample absorbance at 
260 nm and the 260/280 absorbance ratio, respectively. 
2.1.3 Synthesis of peptide 
The peptide gH625-Cys [Ac-HGLASTLTRWAHYNALIRAFK(Mtt)GGGC-NH2] was 
synthesized using standard solid-phase-9-fluorenyl methoxy carbonyl (Fmoc) method, 
Rink Amide resin on a fully automated multichannel peptide synthesizer Biotage® Syro 
Wave™. As concern rhodamine functionalization, Mtt group was removed from lysine 
amino group using DCM/TIS/TFA (95/4/1) solution; Kaiser test was used to confirm the 
complete removal of Mtt groups. Conjugation of rhodamine (rhod) to gH625 peptide was 
performed on solid-phase by a standard coupling procedure in order to bind the lysine side 
chain amine and the rhodamine carboxylic group. The mixture of peptide (1 eq), HBTU 
(3 eq), Oxyma Pure® (3 eq), DIPEA (6 eq) and Rhodamine-B (2.5 eq) in anhydrous DMF 
reacted for 2 h at room temperature under continuous stirring. Then, resin was washed 
several times with DMF, DCM and methanol before. Cleavage of peptide from resin was 
performed by standard TFA/TIS/water (95/2.5/2.5) solution, followed by precipitation in 
cold ethyl ether. The reaction product was verified by analytical LC-MS analysis and then 
purified by RP-HPLC using a 20/80 (v/v) ACN/ 0.1% v/v TFA. MS for rhod-gH625-Cys 
peptide: calculated for [M+H]+ = 3167.73 m/z; found (ESI) [M+3H]3+ = 1056.58 m/z, 
[M+4H]4+ = 792.68 m/z, [M+5H]5+ = 634.35 m/z, [M+6H]6+ = 528.69 m/z. 
In order to verify the secondary structure of gH625-Cys peptide, circular dichroism (CD) 
spectra were recorded using a JASCO J1500 CD spectrometer in a 0.1 cm quartz cell at 
room temperature. The spectra were an average of 15 consecutive scans from 260 to 
190 nm, recorded with a band width of 1 nm, a data pitch of 0.2 nm and a scan rate of 
100 nm/min. Spectra were recorded and corrected for the blank sample. MS and CD 
spectra are subsequently showed and debated within Chapter 3 (Figure 3.2). 
43 
2.1.4 Synthesis gH625-PEG-PEI conjugate  
gH625-PEG-PEI copolymer was synthesized in two steps. First, NHS-functionalized 
carboxylic group of glutamic acid residue of PEG 3.3 kDa and secondary amines of 
PEI polymer chain reacted in order to obtain 2 % PEG branched PEI. Polymer 
functionalization degree is express as percentage of PEI monomeric units that reacted 
with PEG considering that, for a 25 kDa PEI chain consist on ~ 580 [-CH2CH2NH-] 
monomeric units. Briefly, 5 mL of a 2 mg/mL PEI solution in MES buffer, pH 5.5 
(corresponding to 10 mg/0.400 ȝmol PEI; βγβ ȝmol total amine), were added to 
15.58 mg (4.7 ȝmol) of NHS-PEG-Alkyne, previously weighted in a round bottom 
flask. The reaction was carried out for 5 h at room temperature under vigorous 
magnetic stirring. The adducts were purified from unreacted reagents using dialysis 
bags (MWCO 6-8 kDa) against pure water and lyophilized. The reaction products were 
verified by 1H-NMR spectroscopy using deuterated water (D2O) as solvent. The degree 
of PEG substitution was determined by comparing the integral values obtained from 
the number of [-CH2CH2O-] protons of PEG and [-CH2CH2NH-] protons of PEI.33-35 
PEG-PEI copolymer 1H NMR (600 MHz, D2O) attribution refers to Figure 2.2 A:  
δ ppm γ.λγ (t, i); 3.90-3.50 (h); 3.46 (t, g); 3.13 (a); 2.99 (b); 2.58-2.48 (m, e+j);  
2.44 (s, l); 2.26 (t, k); 1.90 (m, g); 1.25 and 1.14 (t, c+c’).  
As regards peptide coupling, 10 mg of the PEG-PEI copolymer (MW ~ 63 kDa),  
that correspond to 1.84 ȝmol of alkyne functional groups, 1.γ0 ȝmol of  
rhod-gH625-Cys and 0.13 µmol of DAROCUR 1173 (used as photoinitiator) were 
dissolved in 10 mM citrate buffer. Thiol-yne reaction were performed by illumination 
of the solution with an UV lamp (Ȝ = γ65 nm) for 10 minutes in static condition.  
After that, magnetic stirring was activated and the mixture reacted for additional  
50 minutes. The amount of peptide has been chosen in order to obtain a resulting 
peptide degree of functionalization of about 1 % of the total PEI amine content 
(verified by NMR spectroscopy). Again, the adducts were purified from unreacted 
reagents using dialysis bags (MWCO 6-8 kDa) against pure water and lyophilized.  
The reaction products were verified by 1H-NMR spectroscopy. Considering the final 
stoichiometry of the copolymer (gH625/PEG/PEI 5.8/11.6/1), MW of the construct was 
estimate to be ~ 82 kDa. 
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gH625-PEG-PEI copolymer 1H NMR (600 MHz, D2O) attribution refers to Figure 2.2 B: 
δ ppm 8.10-7.50 (peptide amide backbone, *); 3.93 (t, i); 3.90-3.50 (h); 3.46 (t, g); 3.13 
(a); 3.00 (b); 2.58-2.48 (m, e+j); 2.45 (s, l); 2.27 (t, k); 1.90 (m, g); 1.25 and 1.14 (t, c+c’).  
2.1.5 Polyplexes preparation  
DNA complexes were formed by addition of cationic polymer (PEI) to plasmid resulting in 
self-assembled colloidal particles.20 For gH625-PEG-PEI/DNA and PEI/DNA complexes 
formation, stock solution (11.6 mM of amine, corresponding to 500 ȝg/mL of PEI β5 kDa) 
of gH625-PEG-PEI copolymer or only PEI were prepared. As regards PEI stock solution, 
10 % of total amines were provided by jetPEI-fluoR in order to realize fluorescent 
polyplexes useful for the following characterization. 
Proper amount of both polymers and plasmid DNA (γ ȝg) solutions were diluted in 50 ȝL 
of 150 mM NaCl water solution, gently vortexed and spun down. After 10 minutes, PEI 
solution were added to DNA solutions, rapidly mixed by pipetting up and down and 
incubated for 20 minutes at room temperature to allow complex formation between the 
positively charged PEI (amine groups) and the negatively charged DNA (phosphate 
groups).36-37 
In order to optimize the complexes formulation, in terms of best transfection efficiency and 
lower cytotoxicity, complexes were generated using different N (nitrogen) to P (phosphate) 
ratios (N/P = 5, 10, 15, 20 and 30). This represents the molar ratio of amine groups of PEI 
to phosphate groups in DNA backbone (usually 3 nmol of P for µg of DNA). Polyplexes 
were created setting the DNA concentration and suitably changing the polymer amount. 
2.1.6 Characterization of DNA complexes 
Obtained gH625-PEG-PEI/DNA and PEI/DNA complexes were physicochemically and 
morphologically characterized. The particle size and zeta-potential were measured by 
dynamic light scattering (DLS) using a Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK). All measurements were done in triplicate, the mean value was 
recorded as the average of three different runs. 
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Thus, confocal laser scanning microscopy (CLSM) was used to effectively verify the 
complexes formation through the detection of plasmid DNA labelled with Hoechst 33342 
staining and rhodaminated polymeric vectors. Polyplexes solution were dropped on a glass 
microscope slide and observed by a Leica Microsystem (Germany) TCS SP5 II SMD 
confocal/multiphoton microscope, equipped with a HCX IRAPO L 25 X/0.95 water 
immersion objective was used to acquire. Emitted light was detected with two 
photomultipliers. Excitation of rhodamine-labeled PEI, was achieved using the 543 nm 
HeNe excitation line, with the resulting fluorescent wavelengths observed in 560-610 nm 
and excitation of DNA-Hoechst 33342 was achieved with the multiphoton Chameleon 
Ultra II Ti/Sapphire NIR femtosecond 80 MHz pulsed laser (Coherent Inc., USA) at 700 
nm excitation line, with the resulting fluorescence observed at 400-480 nm. Confocal 
images were acquired with pinhole aperture of 1AU (Airy Units) corresponding to a 
section thickness of 1.4 ȝm, with a frame size of 10β4×10β4 pixels (equivalent to a field of 
view of 6γ0×6γ0 ȝm2). 
Finally, complex characterization was evaluated using scanning electron microscopy 
(SEM). Prior to imaging, dried samples were mounted to microscope stub and coated with 
7 nm of platinum-palladium under argon atmosphere using a SEM sputter coating system 
(Cressingthon, 208 HR, UK). Samples surface morphology was then observed using a 
scanning electron microscope (Zeiss, FEG Ultraplus, Germany) with an accelerating 
voltage of 8 kV and variable magnifications. 
2.1.7 Modification of glass substrates  
Glass coverslips of 12 mm Ø (Knittel glass, Germany) were used to covalently bind 
gH625-PEG-PEI complexes. In order to provide bonding sites for alkyne-azide click 
chemistry reaction for the polyplexes onto the glass surface, 12 mm diameter glass 
coverslips were firstly treated with 3-bromopropyl trimethoxy silane (BPTMS). BPTMS 
was immobilized to the substrate by silane condensation. 
Prior modification, the glass coverslips were cleaned carefully by immersion in  
acetone and ultra-sonication for 10 min (3 times) and then dried in a nitrogen flow. 
Subsequently, the activation of substrates was carried out immerging the glass coverslips 
in a 0.1 M NaOH solution for 3 minutes, followed by several water and ethanol washes.  
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Then, coverslips were placed in a petri dish and covered with 4 % toluene solution of 
BPTMS (~ 0.5 mL for each coverslip), overnight, slightly agitated on an orbital shaker. 
After the silane treatment, glass coverslips were extensively rinsed with toluene and 
ethanol (3 times each) to remove residual reagent and then dried under nitrogen flow. 
Bromide group was then replaced with azido group by nucleophilic substitution  
SN2 reaction. Azide substitution were performed on bromo-silanized glass coverslips  
using sodium azide saturated solution in DMF (~ 50 mM, ~ 1 mL for each coverslip) and 
let to react under stirring for 24 hours at RT. Afterwards, treated glass coverslips were 
washed with DMF, ethanol and acetone and then dried under vacuum for 2 h. 
2.1.8 Water contact angle 
Surface modification of glass slides, starting with NaOH activation, followed by silane 
immobilization and subsequent bromide-azido substitution, was analyzed by water contact 
angle measurements of water in air at room temperature under static conditions. An 
Attension Theta optical tensiometer (Biolin Scientific, Stockholm, Sweden) was used to 
analyze the different wettability of modified substrates in order to verify to the occurrence 
of chemical modification. A 4 ȝL droplet of MilliQ water was laid on chemically modified 
glass surfaces and the picture was taken with a digital camera. Contact angle was recorded 
as the angle between the point of contact of the droplet with the solid surface and a tangent 
with the droplet profile. The contact angle measurement was estimated from a picture and 
calculated as the mean value of 5 separate measurements on 3 different glass coverslips. 
2.1.9 Binding of PEGylated complexes to modified glass substrate  
Through the activation of glass slides with BPTMS, followed by the bromide-azido 
substitution, azido groups were exposed at surface in order to allow the linking of 
gH625-PEG-PEI/DNA complexes. With the purpose of accomplish the covalent bond 
between complexes and activated glass slides, azido-alkyne click chemistry reaction were 
carried out. Some considerations elucidated in paragraph 2.1.16 have led us to choose the 
following reaction conditions: 0.01 eq of copper sulfate and 0.2 eq of sodium ascorbate 
with respect of total gH625-PEG-PEI used in polyplexes synthesis. After reaction between 
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exposed azido groups, unbound complexes were removed and the substrates were washed 
3 times with PBS and then used for characterization or transection studies. 
In order to evaluate the reaction final yield, we exploited the rhodamine functionalization 
of the gH625-Cys peptide that was monitored by fluorescence measurement before and 
after the reaction. Rhodamine concentration of the unbound complexes was detected via a 
standard curve, by measuring the fluorescence of gH625-PEG-PEI (ex/em 550/570 nm)  
in a multi-well plate spectrofluorometer (Enspire 2300, Perkin Elmer, USA). 
The polyplexes covalent binding efficiency (PCov) was expressed as the difference between 
the complexes concentration initially incubated on the substrate and the concentration  
of unbound complexes after the reaction, normalized on initial concentration,  
in percentage. P஼�� = [P]� − [P]�[P]�  
Where [P]i and [P]f are the initial and final concentrations of polyplexes solutions 
measured before and after process, respectively. The experiments were repeated in 
triplicate with different samples, for each N/P ratio tested. The density of DNA complexes 
immobilized to each sample was determined by normalizing the complexes amount bound 
to area of substrate. After some preliminary tests, the reaction conditions were adjusted in 
order to obtain the same DNA coverage density in both covalent and adsorbed samples. 
2.1.10 Complexes adsorption on glass substrates 
After preparation gH625-PEG-PEI/DNA and PEI/DNA complexes were adsorbed by 2 h 
incubation on glass substrates. Different polyplexes solutions (N/P = 10, 15, 20 and 30) at 
known gH625-PEG-PEI and jetPEI-R concentrations were adsorbed on Ø 23 mm 
Fluorodish (World Precision Instruments Ltd) for 2 h at room temperature. As for the 
binding reaction, the final adsorption efficiency (PAds) was determined by rhodamine 
fluorimetric assay as descripted in the previous paragraph. 
The experiments were repeated in triplicate with different samples, for each N/P ratio and 
the reactant amount and the deposition time were optimized in order to obtain the desired 
DNA coverage density. 
48 
2.1.11 Characterization of substrates  
Substrates and complexes morphology was investigated by scanning electron (SEM) and 
confocal (CLSM) microscopy. Images of adsorbed and covalent bonded polyplexes were 
collected using the same instrument configuration described in paragraph 2.1.6. 
2.1.12 Transfection and cytotoxicity studies 
Transfection efficiency and cell toxicity of the DNA complexes, generated according to  
the different formulations, were tested performing 2D transfection analysis in  
three different ways: bolus delivery and substrate mediate gene delivery of adsorbed  
and bonded complexes. Control studies were performed using un-functionalized  
PEI/DNA complexes. 
For bolus delivery transfection experiments, NIH3T3 cells were seeded in Ø 23 mm 
Fluorodish (World Precision Instruments Ltd) at density of 70,000 cells/dish and incubated 
at 37 °C and 5 % CO2. After 24 h, polymer/DNA complexes (N/P ratio from 5 up to 30; 
1 ȝg of total plasmid DNA), were added to each separate dishes. Conversely, for reverse 
transfection studies of adsorbed polyplexes, the same cell amount was seeded in  
Ø 23 mm Fluorodish already containing adsorbed polyplexes (1 ȝg of total DNA).  
Finally, for reverse transfection studies of covalent bonded polyplexes, NIH3T3 cell were 
seeded on polyplexes Ø 12 mm functionalized glass coverslip placed in a 24 well plate.  
In order to have comparable densities of both cell and plasmid DNA, 19,000 NIH3T3 cells 
were seeded onto chemical bonded polyplexes (~ 0.27 µg of total DNA). 
After β4 h, samples were stained adding 100 ȝL of 1μ10,000 Hoechst 33342 PBS solution 
in each Fluorodish (50 ȝL for β4 well plate). Living cells were directly observed by mean 
of confocal microscopy equipped with an Okolab incubator (Okolab S.r.l., Pozzuoli, Italy) 
for temperature and CO2 control. Analyses of the transfection were carried out using a 
confocal laser scanning microscope using the same condition described in paragraph 2.1.6. 
In addition, excitation of GFP-actin was achieved using the 488 nm Ar excitation line,  
with the resulting fluorescent wavelengths observed in 500-530 nm. 
The effective gene transfer was monitored by expression of reporter transgene encoding 
for green fluorescent protein. Transfection efficiency (number of transfected cells  
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(GFP-expressing cells)/number of cells (Hoechst 33342-stained cells)) were quantified 
through analysis of images using ImageJ software. Each estimation was repeated in 
triplicate on different samples. Results were compared by analysis of variance (ANOVA) 
and a significance level of 95% (P = 0.05) was founded in all cases. 
The biocompatibility of DNA complexes generated according to different formulations 
was evaluated by colorimetric Alamar blue assay (Life Technologies, Grand Island, NY) 
according to the manufacturer’s procedure.38-39 The experimental setup was identical to the 
one just described for transfection studies; un-treated cells were used as a negative control. 
After 24 h of exposure with all kind of DNA polyplexes, the metabolic activity of all cell 
cultures was determined by using standard Alamar Blue assay. Absorbance of Alamar Blue 
reagent solution was read at 570 nm and 600 nm by a plate reader (Enspire 2300, Perkin-
Elmer). All experiments were performed in triplicate and data sets represent the cell 
viability percentage of treated cells normalized to un-transfected cells. 
2.1.13 Statistical analysis  
All quantitative data were reported as means ± standard deviation (SD). Statistical analyses 
were performed using a one-way analysis of variance (ANOVA); a P < 0.05 was 
considered statistically significant. 
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1.3 Results and discussion 
2.1.14 Synthesis and characterization of gH625-PEG-PEI vector 
The gH625-PEG-PEI vector was synthesized through a two-step reaction as shown in 
Scheme 2.1. Hetero-bifunctional NHS-PEG-Alkyne (3.3 kDa) firstly reacted with primary 
and secondary amine of PEI (25 kDa) obtaining PEG branched PEI. This reaction were 
carried out in MES buffer at pH 5.5 in order to avoid the competing hydrolysis reaction of 
the N-hydroxysuccinimide ester that occurred at acidic pH values.40 The modification of 
PEI with PEG was assessed by 1H-NMR spectroscopy in D2O (Figure 2.2 A). In particular, 
in PEI chain region was clearly visible the difference between the peak related to CH2 
protons near to functionalized nitrogen atoms (a, 3.13 ppm) and the original CH2 group of 
classic PEI (b, 3.00 ppm). Results of spectra integration, based on the respective molecular 
weights, indicated that final PEG/PEI ratio in the copolymer was 12 that corresponded to a 
functionalization degree of 2.1 % with respect of total amine content of PEI.41 
 
Scheme 2.1. Reaction outline for the synthesis of gH625-PEG-PEI conjugate: activation of PEI with  
NHS-PEG-Alkyne followed by the addition of the Rhod-gH625-Cys CPP through thiol-yne “click chemistry” 
reaction. (*) Numbers of equivalent are expressed as percentage of the total number of PEG amines (~ 580). 
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The use of PEG linker offered several advantages in reducing unwanted interactions of the 
polyplex with proteins, providing enhanced polyplex stability and lowered toxicity.42  
Moreover, it should be useful to overcome restrictions of pure oligopeptide based 
polyplexes, such as low plasmid complexation ability43-44 and the decrease of polyplexes 
efficiency because of a too strong interaction with the complexed DNA.45 The PEG linker, 
additionally, provided a steric shielding of the cationic PEI core from the peptide sequence 
and, thereby, facilitated the coupling reaction with plasmid DNA. Finally, hydrophilic PEG 
chain divided gH625 peptide from the PEI core promoting a more correct position of the 
oligopeptide moieties on the surface of the polyplexes.46 
In the second step of the reaction, gH625 peptide was coupled to the alkyne group through 
a thiol-yne “click chemistry” photoreaction exploiting the –SH group of Cysteine residue 
at the C-term of the peptide sequence. Rhod-gH625-Cys peptide was synthesized in good 
yield (35 %) and characterized using MS and CD analysis demonstrating the effective 
conjugation of rhodamine to peptide sequence (MW 3167.73 Da) and the correct formation 
of gH6β5 α-helical secondary structure, respectively. 1H-NMR spectrum of the reaction 
product was shown in Figure 2.2 B. 
Generally, as the analogous thiol-ene photoreaction, thiol-yne was used to synthesize 
highly crosslinked polymer networks.47-48 Moreover, due to the double unsaturation degree 
of alkyne group, it was possible to obtain polymer networks with higher crosslinking 
densities than the equivalent thiol-ene networks.49 The kinetics of the polymerization 
process indicated a very fast reaction between thiols and alkynes that, under stoichiometric 
(2 thiols: 1 yne) conditions, gave rise to the monosubstituted vinyl sulfide moiety was even 
more reactive with the thiols than the -yne moiety.47 In this work, in order to avoid double 
peptide-alkyne linkage, an alkyne stoichiometric excess was used. Using this reaction 
conditions, only varying amounts of unreacted alkyne and vinyl sulfide product were 
expected. Even though the interpretation of the NMR spectrum was quite tricky, it was 
possible to observe the signals of peptide amide bond chain at 7.50-8.10 ppm (*) and, 
especially, the drastic reduction of the intensity of the alkyne peak (l). 
Finally, the reaction condition were optimized in order to have a final degree of PEI 
substitution that was calculated to be 2.1 % for PEG and estimated to be almost 1.0 % for 
gH625 whit respect of all amines present in one PEI 25 kDa chain. 
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Figure 2.2. 1H-NMR spectra in D2O of PEG-PEI (A) and gH625-PEG-PEI (B) copolymers with attribution. 
In (B) only peaks related to peptide amide bond backbone (*) and PEG-alkyne proton (l) are highlighted. 
 
2.1.15 Polyplexes physicochemical and morphological characterization 
Different N/P ratio formulations of PEI/DNA and gH625-PEG-PEI/DNA complexes were 
prepared and well characterized in term of size, surface charge and morphology. DLS and 
ζ-potential measurements were carried out using a Zetasizer Nano-ZS. Results indicated 
that, except for the N/P 5 gH625-PEG-PEI/DNA formulation(*), the polyplex size ranged 
from 114 to 160 nm and all of them were positively charged (Table 2.1).  
Table 2.1. Particle size and ζ-potential values for produced polyplexes. Hydrodynamic diameters ad surface 
charges values are reported as means ± standard deviation (SD). 
 PEI only gH625-PEG-PEI 
N/P 
Size 
(nm) 
ζ-Potential 
(mV) 
Size 
(nm) 
ζ-Potential 
(mV) 
5 146 ± 12 19 ± 2 808 ± 54(*) -2 ± 8(*) 
10 147 ± 9 27 ± 3 160 ± 11 10 ± 1 
15 114 ± 8 36 ± 2 145 ± 7 19 ± 4 
20 118 ± 7 38 ± 2 114 ± 5 25 ± 2 
30 122 ± 9 37 ± 1 118 ± 3 28 ± 3 
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packaging is another important parameter to ponder. Indeed, an adequate free volume 
for the polyplexes has to be taken into account in order to overcome aggregation 
phenomena. 
Before use, glass slides were washed, activated by NaOH alkaline treatment and then 
directly modified with a bromo-metoxy silane. After silanization, the bromide atoms 
were displaced by sodium azide in DMF. Water contact angle (WCA) measurements 
were carried out on the substrate before the NaOH treatment and after each further 
modification step. The acquired data were in good agreement with those already 
reported in literature66 confirming the occurrence of every reactions (Table 2.2).  
In particular, for bromo-silanized glass was found a WCA average of 91°, while after 
azide SN2 reaction the average WCA decrease to 77°. 
Table 2.2. Water contact angle (WCA) values and drop pictures on glass coverslips after each substrate 
modification step. 
Sample WCA Drop picture 
Glass coverslip 68° ± 3° 
 
NaOH activation 41° ± 0.9° 
 
BPTMS layer 91° ± 3° 
 
Azido silane layer 77° ± 2° 
 
Finally, gH625-PEG-PEI complexes were linked to modified glass substrates via a specific 
azide-alkyne click reaction. All the synthesis steps were outlined in Scheme 2.2. 
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Scheme 2.2. Schematic synthesis steps of glass surface functionalization with PEI-PEG-gH625 polyplexes. 
Once surface exposure of azide moieties has been achieved by SN2 nucleophilic substitution, azido-alkyne click 
chemistry reaction was carried out in order to covalently bind functionalized polyplexes to the substrate. 
Generally, for click reaction 0.5 eq of CuSO4 and 10 eq of sodium ascorbate were used, 
based on the amount of alkyne group.59-60 Considering our final goal that, ideally,  
was to bind a polyplex through a single PEG linker chain, there are some consideration 
that influenced the reaction condition adopted: (i) theoretically, a single polyplex  
is made by 5 up to 10 PEI molecules, (ii) there is an average of ~ 6 free alkyne group 
for each PEI molecule and (iii) Copper (I) ions and ascorbate attended the reaction  
as catalytic and not stoichiometric players. Thus, final copper (I) and ascorbate 
amounts were scaled of 50 times (0.01 eq and 0.2 eq, respectively) with respect of  
total gH625-PEG-PEI used in polyplexes synthesis. Moreover, in order to  
avoid multiple anchoring sites and to achieve a layout density control, the reaction  
was carried out for only 15 minutes. Finally, the DNA coverage density control in  
both covalent and adsorbed samples was achieved by modifying the reactant  
amount and the reaction time based on the polyplexes covalent binding efficiency 
(PCov). 
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2.1.17 Substrates characterization 
Morphological features of complexes modified substrates were analyzed by confocal 
(CLSM) and electronic (SEM) microscopy. Both of them have proven to be an 
excellent tool for imaging of soft biological structures and can be performed with high 
resolution after complex deposition on a surface. SEM (Figure 2.5) and CLSM  
(Figure 2.6) images of covalent bonded (A-A’) and adsorbed (B-B’) gH6β5-PEG-PEI 
polyplexes were obtained by scanning glass slides with immobilized complexes in wet 
and dry conditions, respectively. Images reveal the typical globular morphology of 
complexes and their surface distribution on activated substrates.67-69 
In particular, Figure 2.5 B showed a high density of adsorbed polyplexes on  
substrate. This demonstrates the expected complexes aggregation, as shown also  
by the dimensions of fluorescent spots presented on substrates in the related  
confocal images (Figure 2.6 B-B’). On the other hand, Figure 2.5 A and  
Figure 2.6 A-A’ highlighted the absence of aggregation of complexes on  
substrates during the covalent binding process. This observation supported  
and encouraged the synthetic approach and procedures used in this work. This  
strategy showed several advantages in overcoming problems related to reagent 
consumption and cell population heterogeneity effect, making these systems attractive 
for a wide range of assays, from drug discovery to toxicology, stem cell research  
and therapy. In this way it can be possible to control the spatial distribution  
and concentration of different polyplexes formulation. 
 
Figure 2.5. Scanning electron microscopy images of covalent bonded (A) and adsorbed (B) polyplexes on 
glass surface. Scale bars: 200 nm. 
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Figure 2.7. Cytotoxicity assay of PEI/DNA and gH625-PEG-PEI/DNA polyplexes at different N/P ratios in 
NIH-3T3 cells after 24 h of incubation. Experiments were carried out in direct (bolus delivery) and reverse 
(with absorbed or covalent bonded polyplexes) transfection mode. Bars highlighted with symbols are 
statistically different (p < 0.05). 
Generally, the polymer toxicity is directly related on the interaction of the PEI/DNA 
complexes with cell membranes which generally increases with positive charges exposed 
on the surface, proportionally to N/P ratio.70 In particular, the polycationic polymers  
(like PEI) undergo strong electrostatic interaction with plasma membrane proteins,  
which can lead to destabilization and ultimately rupture of the cell membrane.  
Fischer et al.71 demonstrated that the cytotoxicity of different types of  
polycationic polymers depends on the number and arrangement of the cationic  
charges which determines the degree of interaction with the cell membranes. The cells, 
exposed to cationic polymers, first show membrane leakage followed by a decrease  
in the metabolic activity.70 In our case, the addition of gH625-PEG functionality  
masks the positive charge of the PEI molecules, reducing the positive charge  
exposed at the surface and further decrease the complexes toxicity.67, 72-73 
However, polyplexes cellular uptake was not affected by the adding of the gH625-PEG 
moiety. In Figure 2.8 was possible to appreciate the distribution of PEI (A) and  
gH625-PEG-PEI (B) rhodamine-labelled polyplexes where complex (B) exhibited  
an extremely higher cellular uptake, as well as the good transfection ability, granted  
by the gH625 CPP. 
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Figure 2.8. Confocal images of NIH-3T3 cells treated with PEI/DNA (A) and gH625-PEG-PEI/DNA (B) 
polyplexes at N/P = 20 in bolus delivery experiments. Scale bar: 10 µm. 
Furthermore, transfection experiments were carried out on NIH-3T3 cells using identical 
conditions, as described for cytotoxicity studies. Gene-delivery efficiencies were 
calculated as the number of transfected cells (expressing the green fluorescent protein) 
normalized on total number of cell. Results clearly indicated an improvement of gene 
transfection of the gH625-PEG-PEI vector with respect of PEI/DNA complexes almost at 
every N/P ratio in bolus and substrate adsorbed delivery (Figure 2.9). 
 
Figure 2.9. Transfection assay of PEI/DNA and gH625-PEG-PEI/DNA polyplexes at different N/P ratios in 
NIH-3T3 cells after 24 h of incubation. Experiments were carried out in direct (bolus delivery) and reverse 
(with absorbed or covalent bonded polyplexes) transfection mode. Bars highlighted with symbols are 
statistically different (p < 0.05). 
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The enhancement of transgene expression was well supported by the increased cellular 
uptake of DNA complexed with gH625. The fusogenic peptide functionalization 
resulted in a significant increase of the number of transfected cells, also increasing the 
level of polyplexes uptake by individual cells as showed by fluorescence microscopy 
images (Figure 2.8). In addition, cytosolic localization of the DNA was substantially 
improved. 
Although the bolus delivery approach showed improvements in transfection efficiency 
for polyplexes at N/P 20, gene delivery method with adsorbed complexes at N/P 20 
and 30 lead to the best results. Altogether, the combination of gene delivery efficiency 
with a substantial absence of toxicity, makes these formulations the starting point for 
further experimental investigations. 
Unluckily, experiments fulfilled using covalent bonded polyplexes did not give the 
expected results. While cytotoxic assay of linked polyplexes can be collected as a 
really good result, transfection efficiency of the functionalized platform was practically 
negligible. Probably, the covalent linkage represents a too strong connection and, 
therefore, if the association of gene particles with a substrate is too tight, endocytic 
uptake and transfection can suffer. As evidence, no significant differences were found 
on the coverslip surfaces before and after the experimental sessions, sign of much 
lower complexes internalization.  
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1.4 Conclusions 
In this chapter we developed a new non-viral gene delivery vector based on gH625 
CPP, by crosslinking 25 kDa PEI with 3.3 kDa PEG, further coupled with the peptide 
through a thiol-yne click chemistry photoreaction. All the synthesis steps were carried 
out with good yields and the product were characterized using 1H-NMR spectroscopy. 
We confirmed that gH625-PEG-PEI vector had the ability to form complexes with 
plasmid DNA at various N/P ratio and showed suitable physico-chemical properties for 
gene delivery, such as narrow size distribution and positive surface charge. The new 
vector was able to increasing general polyplexes cellular uptake and cytosolic delivery 
in NIH-3T3 cells both in direct and reverse transfection methodologies. Furthermore, 
the new gene delivery vector showed much lower cytotoxicity and higher gene 
transfection efficiency compared with PEI 25 kDa. The best performances were found 
in substrate-mediate gene delivery experiments using adsorbed polyplexes at N/P ratio 
of 20 and 30. 
As regards the poor efficiency of the covalent bonded polyplexes, this result should not 
be discouraged. Numerous advantages coming from the developed strategy can be 
exploited in order to perform substrate functionalization. This approach represents a 
promising tool in performing a molecule-substrate linkage with a selective and facile 
chemistry, without undesired sub-product and achieving a controlled and homogeneous 
distribution of the linked molecules. Concerning covalent gene delivery, we are 
optimistic for forthcoming approach based on linker that can assure a very quick 
release of the polyplexes, such as cleavable peptides or fast biodegradable polymers.  
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Chapter 3  
 
 
Size and gH625-functionalization affect 
cytosolic delivery of platinum nanoparticles* 
 
 
Abstract. The ability of gH625 membranotropic peptide to deliver PtNPs free in the 
cytosol, by escaping endo-lysosomal pathway, strongly depends on particle size. In 
particular, peptide functionalization elicits a significant enhancement of NP cellular 
uptake, though with a prevalent confinement in vesicular structures. Only for the smallest 
2.5 nm size, a partial cytosolic localization was observed. Combining the enhanced uptake 
and partial cytosolic delivery promoted by gH625, a strong improvement of the antioxidant 
nanozyme function of 2.5 nm PtNPs was achieved. 
 
 
 
 
 
 
 
 
 
 
 
* The work described in this Chapter is part of a published manuscript: Guarnieri, D., Melone, P., 
Moglianetti, M., Marotta, R., Netti, P. A. and Pompa, P. P. (2017). “Particle size affects the 
cytosolic delivery of membranotropic peptide-functionalized platinum nanozymes.” Nanoscale, 
9(31), 11288-11296. All the figures and table are reproduced or adapted from Ref. 1 with permission 
from The Royal Society of Chemistry  
70 
3.1 Introduction 
One of the main challenges of nanomedicine is to guide therapeutic agents towards their 
specific intracellular target, thus improving their efficiency and avoiding side effects.  
To this aim, drug molecules and nanoparticles (NPs) should cross the highly selective cell 
membrane to gain access to the interior of the cell and exert their biological functionality. 
In general, apart from some exceptions (e.g. small non-polar species), molecules and NPs 
cannot directly overcome the lipid bilayer and are usually internalized by cells according to 
“classical” endocytosis mechanisms.2-3 Nevertheless, NPs are typically used as Trojan 
horses since they allow high intracellular transport of bioactive molecules that cannot 
otherwise enter the cells, reducing their fast clearance and side effects.4-6 Following 
endocytosis, however, nanomaterials become entrapped in vesicular compartments 
(endosomes/lysosomes), where the very low pH and the presence of specific enzymes 
generally cause degradation of the internalized material.7-9 As a consequence, the 
accumulation of nanomaterials inside endo-lysosomes significantly reduces their 
therapeutic potential and, sometimes, impairs cellular functions.7-11 Therefore, shuttling 
nanoparticles across cell membrane directly into the cytosol by avoiding endocytosis or 
facilitating endo-lysosomal escape would have a large impact in improving the efficacy of 
NP-based therapy. To address this issue, several strategies have been explored in recent 
years, including microinjection, electroporation and endosome lysis through osmotic shock 
(the so called “proton sponge effect”), but they have shown some limitations due to their 
invasiveness and cytotoxicity.2, 12-15  
In this framework, the discovery of cell-penetrating peptides (CPPs), small molecules that 
can be used as shuttles to deliver bioactive compounds inside cells, has opened new routes 
for designing effective approaches for intracellular delivery of drugs and nanoparticles.16-18 
Among these, virus-derived peptides, such as the positively charged TAT (derived from 
HIV-1) and the hydrophobic HA2 (derived from influenza A virus), have been widely 
employed to functionalize molecules and nanoparticles, in order to enhance their 
internalization and to avoid lysosomal accumulation at the same time.16 Several studies 
have demonstrated that CPPs can improve cellular uptake of nanomaterials.19-21  
However, clear delivery of peptide-functionalized nanomaterials into the cytoplasm has not 
been fully proved yet, and conflicting findings are reported in the literature.22-24 
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Nativo et al. showed that 16 nm gold NPs functionalized with a combination of TAT, 
penetratin and PEG were partially localized free in the cytosol of HeLa cells.24  
Moreover, Berry et al. reported the possibility to deliver TAT-functionalized Au-tiopronin 
NPs, with an original hydrodynamic diameter of 2.8 nm, to the nucleus of primary human 
fibroblasts.22 Oh and co-workers indicated that TAT-functionalized 2.4 nm gold NPs were 
able to cross nuclear membrane, while 16 nm and larger gold NPs were not able to be 
uptaken by cells.23 On the other hand, Cesbron et al. recently demonstrated that,  
while endocytosis-mediated uptake significantly increased when the TAT and/or HA2  
viral peptides were present on the surface of gold NPs with 5 and 10 nm diameters,  
no significant cytosolic delivery was observed.25 Therefore, these results make difficult to 
formulate a general rule to predict the behavior/fate of CPP-transported NP cargoes.  
In addition, this scenario includes further complexity, because in many studies CPPs are 
typically combined with a wide range of surface molecules, including PEG,  
other stabilizing moieties, tracer elements and targeting agents, which might have a role in 
cell interaction and uptake.26-30 
Among other groups, we hypothesized that the size of the NPs linked to the CPP may 
affect the CPP performance and even modify its uptake mechanism, with consequences in 
the final intracellular localization of the delivered cargo. In this work, we thus investigated 
the ability of a membranotropic peptide, namely gH625, to escape the endo-lysosomal 
compartment and deliver NPs within the cytoplasm, as a function of the NP size.  
We carried out a systematic assessment of cellular uptake of monodisperse platinum 
nanoparticles (PtNPs) – with different diameters (2.5, 5 and 20 nm, named Pt2.5, Pt5 and 
Pt20, respectively) citrate capped or covalently functionalized with the gH625 peptide 
through a thiol bonding – on human cervix epithelioid carcinoma (HeLa) cells.  
We combined inductively coupled plasma atomic emission spectroscopy (ICP/AES), 
scanning transmission electron microscopy (STEM) and electron tomography (ET) 
analysis to find a correlation between size and surface functionalization of PtNPs with their 
final intracellular localization. Moreover, ROS generation assays were carried out to 
investigate the potential effect of gH625 in modifying the cellular interaction of PtNPs  
and improving their antioxidant properties. 
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3.2 Experimental section 
3.2.1 Materials 
N,N-diisopropylethylamine (DIPEA), O-benzotriazole-N,N,N’,N’-tetramethyluronium-
hexafluoro-phosphate (HBTU), Ethyl (hydroxyimino)cyanoacetate (OxymaPure®), 
anhydrous N,N-dimethyl-formamide (DMF), Acetonitrile (ACN), rhodamine B, 4-
(dimethylamino) pyridine (DMAP), Dichloromethane (DCM), Methanol, Piperidine, 
Trifluoroacetic acid (TFA), Triisopropylsilane (TIS), Acetic Anhydride, HPLC-grade 
water, 2,2,2-trifluoroethanol (TFE) and all buffer solutions were purchased from Sigma-
Aldrich (USA). All Fmoc-aminoacids were purchased from IRIS Biotech GmbH 
(Germany). Distilled and deionized water used Millipore Milli-RO 10 Plus (Millipore, 
USA) at 18 MΩ resistance. 
3.2.2 Platinum nanoparticle synthesis and characterization 
Pt5 and Pt20 NPs were synthesized as previously reported.30 Pt2.5 NPs were synthesized 
by adding 5γ ȝL of 0.5 M H2PtCl6 (BioXtra grade, Sigma Aldrich) to 90 mL of MilliQ 
water, already heated up to 100 °C. Then, 2.2 mL of a solution containing 1 % sodium 
citrate and 0.05 % citric acid was added. Under vigorous stirring, 1.1 mL NaBH4 at 0.08 % 
was added to the reaction vessel. The vessel was kept under stirring for another 
10 minutes. The NP suspension was then extensively purified with 2 mM sodium citrate 
solution by using 3K Amicon centrifugal filters. The morphology of the produced PtNPs 
was analyzed by transmission electron microscopy (TEM) (JEOL JEM 1011), operating at 
an accelerating voltage of 100 kV. Several images were collected to determine the size 
distribution of the NPs (n = 300) and ICP measurements were made to calculate NP 
concentrations. 
3.2.3 Synthesis of Rhodamine-gH625-Cys peptide 
The peptide gH625-Cys [Ac-HGLASTLTRWAHYNALIRAFK(Mtt)GGGC-NH2] was 
synthesized using standard solid-phase-9-fluorenyl methoxy carbonyl (Fmoc) method. Mtt 
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group was then removed from lysine amino group using DCM/TIS/TFA (95/4/1) solution; 
Kaiser test was used to confirm the complete removal of Mtt groups. Conjugation of 
rhodamine (rhod) to gH625 peptide was performed on solid-phase by a standard coupling 
procedure. The mixture of peptide (1 eq), HBTU (3 eq), Oxyma Pure® (3 eq), DIPEA  
(6 eq) and rhodamine-B (2.5 eq) in anhydrous DMF reacted for 2 h at room temperature 
under continuous stirring. Then, the resin was washed with DMF, DCM and methanol 
before cleavage of rhod-gH625 peptide from resin by TFA/TIS/water (95/2.5/2.5) solution 
and precipitation in cold ethyl ether. The reaction products were verified by analytical  
LC-MS analysis and then purified by RP-HPLC using a 20/80 (v/v) ACN/ 0.1% v/v TFA. 
MS for rhod-gH625-Cys peptide: calculated for [M+H]+ = 3167.73 m/z; found (ESI) 
[M+3H]3+ = 1056.58 m/z, [M+4H]4+ = 792.68 m/z, [M+5H]5+ = 634.35 m/z,  
[M+6H]6+ = 528.69 m/z. To verify the secondary structure of rhod-gH625-Cys peptide, 
circular dichroism (CD) spectra were recorded using a JASCO J1500 CD spectrometer in a 
0.1 cm quartz cell at room temperature. The spectra were an average of 15 consecutive 
scans from 260 to 190 nm, recorded with a band width of 1 nm, a data pitch of 0.2 nm and 
a scan rate of 100 nm/min. Spectra were recorded and corrected for the blank sample. 
3.2.4 Peptide conjugation to PtNPs 
Peptide-NP functionalization was performed by means of the thiol group in the side chain 
of the C-terminal cysteine (C) that is able to make a covalent bond with platinum 
surface.31 Based on NP size and in order to achieve the same surface functionalization  
(in terms of number of peptides per surface units), we explored a broad range of 
peptides/NP ratios trying to accomplish a balance between functionalization efficiency and 
colloidal stability (Table 3.1). 
Table 3.1. Theoretical surface densities of gH625 peptide as a function of particle size and peptide/NPs ratios. 
Theoretical 
surface density 
(n° peptide/nm2) 
Peptide/NP ratio 
Pt2.5 Pt5 Pt20 
0.09 2 5 100 
0.18 4 10 200 
0.27 6 15 300 
0.36 8 20 400 
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NPs were functionalized with rhodamine-gH625 peptide by simply adding proper volumes 
of NP suspension to peptide water solution, mixing by gently pipetting up and down until 
suspension was homogenized and let to react for 30 min at room temperature. To evaluate 
the functionalization efficiency, NPs were centrifuged at 14.8×103 rpm for 40 min.  
After centrifugation, the supernatant was collected and the rhodamine fluorescence 
intensity was measured in order to evaluate the amount of unbound peptide via fluorimetric 
assay (ex/em 550/570 nm). Measurement values were interpolated with the standard  
curve to obtain peptide concentration. The starting peptide concentration was considered  
as 100 %. 
3.2.5 Cell culture 
Human cervix epithelioid carcinoma (HeLa) cells (ATCC) were cultured in Dulbecco’s 
Modified Eagles Medium (DMEM, Invitrogen) supplemented with 10% (v/v) fetal bovine 
serum (FBS, Hyclone), 100 U/mL penicillin and 100 mg/mL streptomycin (Invitrogen). 
Cells were maintained in incubator at 37 °C under a humidified controlled atmosphere  
and 5 % CO2. 
3.2.6 Cell uptake experiments 
The amount of internalized NPs per cell was quantified by Inductively Coupled Plasma 
Atomic Emission Spectroscopy (ICP-AES). 5×105 HeLa cells were seeded in 6-well plates 
and treated with gH625-functionalized and non-functionalized PtNPs with 2.5, 5 and 
20 nm diameters at the concentration of 50 ȝg/ml for β4 hours. The untreated cells were 
used as a control. After incubation, the cells were washed three times with sterile PBS  
to remove non-internalized NPs, detached by trypsinization and further washed twice  
with sterile PBS by centrifugation. The number of cells was determined by using  
Burker chamber. The samples were digested overnight with 1 mL of aqua regia.  
The solution was then diluted to 5 mL with MilliQ water and directly analyzed by  
ICP-AES (iCAP 6300 DUO, ThermoFisher). 
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3.2.7 Transmission electron microscopy 
HeLa cells were incubated 24 hours with gH625-functionalized and non-functionalized 
Pt2.5, Pt5 and Pt20 nanoparticles and processed as previously reported.30 Briefly, after 
nanoparticle incubation, the cells were fixed for 1 h in 1.2 % glutaraldehyde in 0.1 M 
sodium cacodylate buffer (pH 7.4), post fixed in 1 % osmium tetroxide in the same buffer 
and en bloc stained with 1 % uranyl acetate aqueous solution. The cells were then 
dehydrated in a graded ethanol series and embedded in epoxy resin (Epon 812, TAAB). 
Semi-thin and thin sections of the embedded cell monolayer were cut with an 
ultramicrotome (UC6, Leica) equipped with a diamond knife (Diatome). Both projection 
images and tilt series were acquired in STEM mode working in High Angular Annular 
Dark Field (HAADF) geometry, using a FEI Tecnai F20 transmission electron microscope 
operating at 200 kV and equipped with a Schottky field-emission gun. The tilt series were 
acquired from 400 nm (for the tomography shown in Figure 3.9 A) and 100 nm (for the 
tomography shown in Figure 3.9 B-D) thick sections tilted over ± 60 degrees applying the 
Saxton tilt increment scheme with a 0 tilt step of 3 degrees32 with a magnification of 75000 
and 22500 times corresponding to a final pixel size of 1.30 and 0.46 nm, respectively. 
Computation of the dual tilt tomogram was carried out with the IMOD software  
package.33 Segmentation and 3D visualization were carried out using the Amira package 
(FEI Visualization Science Group, Bordeaux). 
3.2.8 DCF assay 
3×104 HeLa cells were seeded in 96-well microplates and treated with functionalized 
gH625-Ptβ.5 NPs at a final concentration of 50 ȝg/ml. After 48 hours of cell-NP 
interaction, the dichlorofluorescein (DCF) assay was performed. Briefly, the cells were 
washed with HBSS and incubated with 5 ȝM DCFH-DA in HBSS for 45 min at 37 °C. 
The cells were washed with HBSS and the DCF fluorescence intensity was measured by 
using a plate reader (Synergy HT, BioTek – ex/em 480/520 nm). The results were 
normalized with respect to the negative controls (expressed as 100 %). To verify the ROS 
scavenging activity of PtNPs, HeLa cells were also treated for 5 min with 1 mM H2O2 after 
48 h incubation with NPs and 45 min staining with 5 ȝM DCFH-DA. 
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3.3 Results and discussion 
3.3.1 Synthesis and characterization of gH625-functionalized PtNPs 
gH625 is a peptide derived from the glycoprotein H (gH) of the Herpes simplex virus 1 
(20-residue). Several studies demonstrated that it is recognized as a membrane perturbing 
domain,34 and contribute to their merging interacting with model membranes.35 Moreover, 
it is proved that this peptide can transport different kind of cargo, such as NPs, dendrimers, 
quantum dots and liposomes, both into the cell and across the brain endothelium. In this 
way, gH625 is able to reduce the accumulation of NPs as large aggregates into the 
lysosomes and enhance significantly the cell uptake and.36-42 For these reasons, this peptide 
could offer several advantages in escaping endo-lysosomal compartments, making gH625 
a good candidate for the delivery of free nanoparticles in the cytosol. In particular, 
platinum nanoparticles with different diameters (2.5, 5 and 20 nm) were synthetized by 
optimization of a previously reported method.30 Images obtained by transmission electron 
microscopy of bare (citrate capped) nanoparticles showed homogeneous distribution of 
both size and shape for all three preparations (Figure 3.1 A-D). 
 
Figure 3.1. TEM images of bare PtNPs with (A) 2.5, (B) 5 and (C) 20 nm diameters. Scale bar 50 nm. 
(D) Size distribution of Pt2.5, Pt5 and Pt20 NPs calculated by TEM image analysis (n~300) and reported in the 
chart. (E) Quantification of peptide binding efficiency obtained by using peptide/NP ratios reported in Table 
3.1. Functionalization percentages were calculated as difference of initial peptide concentration (100 %) and 
unbound peptide recovered after the reaction with nanoparticles. Data are reported as mean ± SD. 
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3.3.2 Cell uptake and intracellular localization of gH625-functionalized PtNPs 
The ability of gH625 to facilitate the intracellular delivery of PtNPs was tested as a 
function of the particle size. We previously quantified the amount of internalized NPs by 
ICP/AES. Then we evaluated the uptake by HeLa cells of bare and functionalized PtNPs 
after 24 h incubation as reported in Figure 3.3. 
 
Figure 3.3. Quantification of NP cellular uptake by ICP/AES analysis after 24 h incubation 
with 50 ȝg/ml NP suspension in cell culture medium. Data are reported as mean ± SD. 
According with literature,30 bare PtNPs were internalized in cells in a size-dependent 
manner. Interestingly, functionalized NPs showed a significantly higher cellular uptake 
than bare NPs, maintaining higher internalization for smaller NPs. The uptake efficiency 
gain promoted by the peptide was particularly evident for the smallest 2.5 nm particles. 
Notably, we observed a ca. 4-fold increase for gHPt5 and gHPt20 NPs and a 12-fold 
increase for gHPt2.5 NPs with respect to pristine particles. These results suggest that the 
ability of gH625 peptide to enhance NP cellular uptake is strongly limited by the size of 
the NP cargo. These results confirm previous study, showing that the uptake increase in 
presence of gH625 peptide was less than 2-fold for 100 nm polystyrene NPs in bEnd.3 cells.41 
Moreover, gH625 is able to fuse with the lipid bilayer through both electrostatic and 
hydrophobic interactions that work in concert to mediate membrane penetration.43  
In particular, the aromatic residues in the gH625 peptide chain allow its insertion into  
the membrane interface, while the basic residues stabilize this interaction by linking  
the negatively charged head-groups, as shown in other systems.44-46 Therefore the 
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Focusing on the STEM images, we found that there was an increment of NP density per 
endo-lysosomal unit area (Figure 3.5) that was influenced by both size and peptide 
functionalization, according with ICP/AES results (Figure 3.3). In particular, gHPt2.5 
showed significant internalization efficiency, reaching a density of ca. 14,000 NPs/ȝm2 in 
endo-lysosomes (Figure 3.5). 
 
Figure 3.5. Semi-quantitative analysis of gH625-functionalized and bare Pt2.5, Pt5 and Pt20 NP density into 
endo-lysosomal compartments. Inset represents endo-lysosomal density of Pt20 and gHPt20 NPs with a lower 
scale of y-axis. Data are reported as mean ± s.e.m. 
A more detailed analysis of these structures revealed the presence of gHPt2.5 NPs in close 
proximity to the inner part of the endo-lysosomal membrane, some NPs perfectly 
interposed in the membrane bilayer and some others were found outside the vesicles and 
free in the cytoplasm (Figure 3.6 A-C). The percentage of the gHPt2.5 NPs found free in 
the cytoplasm with respect to the total of internalized NPs was calculated to be about 
3.3 %, a value almost 7-fold higher than 0.5 % of non-functionalized Pt2.5 NPs (Figure 
3.6 F). Larger gHPt5 NPs were also able to escape endo-lysosomal compartments, but with 
a very low efficiency (ca. 0.5 %), regardless of surface functionalization (Figure 3.6 D-F). 
Concerning the 20 nm particles, neither Pt20 nor gHPt20 were observed as free in the 
cytosol (Figure 3.6 F), indicating no effect of gH6β5 peptide in transporting large (≥ 5 nm) 
NPs across the endo-lysosomal membrane toward the cytosol. Focusing the attention on 20 
nm NPs, we found very few platinum fragments both inside and outside the endo-lysosome 
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vesicles (Figure 3.7 A). Most of these fragments, deriving from minor lysosomal 
degradation of the flower-like nanostructures, showed a size ranging from 1 to 2 nm 
(Figure 3.7 B), thus smaller or comparable to Pt2.5 NPs, which showed some ability to 
cross the endo-lysosomal membrane. No particles of any size were observed in the cell 
nucleus. 
 
Figure 3.6. Representative STEM images of HeLa cells after 24 h of incubation with gH625-functionalized 
Pt2.5 NPs (A-C) Pt5 NPs (D-E) at 50 ȝg/ml particle concentration. Worth of note the presence of some endo-
lysosomal compartments completely full of particles, NPs crossing the endo-lysosomal membrane and free in 
the cytoplasm (yellow arrows). Scale bars: 100 nm (A-C), 500 nm (D) and 200 nm (E). (F) Semi-quantitative 
analysis of Pt2.5 NPs out of endo-lysosomal compartments. Data are reported as mean ± SD. 
 
Figure 3.7. (A) STEM image of HeLa cells after 24 h of incubation with gH625-functionalized Pt20 NPs at 
50 ȝg/ml particle concentration, showing some particle fragmentation inside and outside the endo-lysosomal 
compartment. Scale bar 100 nm. (B) Size range analysis of particle fragments with a peak around 1-2 nm. 
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STEM images of cell membrane, revealed that gHPt2.5 NPs went into the cell as small or 
large aggregates through clathrin-coated pits (Figure 3.8 A) and membrane invaginations 
(likely macropinosomes) (Figure 3.8 B) and, in a minor fraction, as single particles 
penetrating lipid bilayer directly (Figure 3.8 C-D). 
               
Figure 3.8. STEM images of gHPt2.5 NPs approaching cell membrane. (A) small NP aggregate entering 
through a large putative clathrin-coated pit; (B) large NP aggregates entering by macropinocytosis; 
(C) single NPs penetrating cell membrane and reaching directly the cytosol; (D) zoomed image of dashed 
squared areas in (C). Scale bars: 100 nm (A) and 200 nm (B-D). 
STEM HAADF electron tomography (ET), done after 24 h incubation with gHPt2.5 NPs, 
allowed to obtain a 3D reconstruction of HeLa endolysosomes. With this high-resolution 
images we were able to confirm the localization of NPs inside these organelles,  
a small fraction of nanoparticles outside them (Figure 3.9 A), as well as their presence  
in the lipid bilayer (Figure 3.9 B-D). In particular, focusing on Figure 3.9 C and D,  
it is possible to note membrane crossing by 2.5 nm functionalized NPs, which  
seems to occur by diffusion through the lipid bilayer, with no evident membrane  
damage. 
83 
 
Figure 3.9. STEM HAADF electron tomographies (ET) of endosomal compartments in HeLa cells after 24 h 
incubation with gHPt2.5 NPs indicating particle intracellular distribution. Endosomal membranes and PtNPs 
are pseudo-colored respectively in violet and yellow. (A-B) 3D reconstruction obtained from tomograms of 
endosomes containing clusters of gHPt2.5 NPs. (A slices 1-2) Details of single slices extracted from tomogram 
in (A) indicating NP localization. Black arrowheads indicate particles localized in the cytosol. 
(C) Zoomed image of the region highlighted by the white square in (B) showing NP diffusion through the 
lysosomal membrane. (D) Details of a single slice extracted from the tomogram in (B) indicating NPs 
interposed between the lipid bilayer of endo-lysosomal membrane highlighted in violet (black arrowheads). 
Scale bars are 100 nm in a slice1-2 and 30 nm in (D). 3D projections in A and B have the same magnification 
of A slice1 and D, respectively. 
The amphipathic nature of gH62547 let it to transport cargoes across the endolysosomal 
membrane providing a particular tropism for lipid membranes.35 Moreover, gH625 is able 
to fuse with liposomes36 and to interact prevalently with cholesterol of synthetic lipid 
membranes.48 Especially, its shuttling function is drastically reduced upon cholesterol 
depletion in mouse brain endothelial cells.41 Our results showed that gH625 improved the 
interaction with lipid bilayers, facilitating particle uptake. Though, the presence of a 
differently-sized cargo, covalently bound to the peptide, strongly affects gH625 
performance, in terms of membrane penetration and lysosomal escape. It could be 
explained considering the hindrance of the NPs that limits the interaction of gH625 with 
the lipid bilayer, especially in terms of its transient destabilization enabling membrane 
crossing. This is consistent with our findings of undetectable peptide effects with 5 and 
20 nm PtNPs, which are too big with respect to ~7 nm thick membrane to preserve the 
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membranotropic functionality of the conjugated peptide.  Our hypothesis are in agreement 
with Cesbron et al. work that showed a significant increase of cellular uptake of 5 and 
10 nm AuNPs functionalized with TAT and/or HA2 peptides, with a prevalent vesicular 
confinement and no cytosolic delivery of NPs.25 
In addition, we observed that for particles of 2-3 nm size, that is ca. 3-fold smaller than cell 
membrane thickness, part of the gH625 functionality is preserved and some NPs are 
delivered free in the cytosol following direct membrane penetration. In general, different 
behaviors could be observed as a function of the specific peptide-NP couple, since several 
NP properties (e.g. material, size, shape, surface chemistry, stability and protein corona) 
may affect its interaction with the cell. Peptide surface density and peptide-surface 
interactions could influence the efficiency of direct membrane crossing. Moreover, the NP 
dispersion/agglomeration in culture medium can strongly influence the cytosolic delivery 
mediated by the conjugated peptides, as membranotropic activity can more likely occur at 
single-particle level (as observed for example in Figure 3.6 and Figure 3.8), while NP 
agglomerates are likely uptaken through macropinocytosis and confined in endosomes. 
Therefore, in order to reduce and prevent NP aggregation in cell culture medium we can 
improve the direct diffusion of single gH625-NPs across the membrane, especially in the 
case of the smallest particles (2.5 nm).49 
3.3.3 Antioxidant activity of gH625-functionalized PtNPs 
Several works were focused on the properties of PtNPs as efficient catalysts50-52 and potent 
antioxidants.53-55 Kim et al. reported the enhancement of the antioxidant activity of 2.4 nm 
PtNPs functionalized with a TAT fusion peptide in C. elegans.56 In addition, recently It has 
been demonstrated that Pt5 and Pt20 NPs can act as nanozymes, with strong catalase-, 
peroxidase- and superoxide dismutase-like activities,30 and were able to restore 
physiological reactive oxygen species (ROS) homeostasis in an experimental model of 
oxidative stress-related disease.30 Here, we focused on the possibility to use gH625 to 
improve the ROS scavenging activity of Pt2.5 NPs in HeLa cells, exploiting the highly 
increased particle uptake and partial cytosolic delivery promoted by the peptide. 
Firstly, we evaluated the cellular level of endogenous ROS upon incubation with Pt2.5 and 
gHPt2.5 NPs, since an increment of ROS generation is often associated to cell-NP 

86 
3.4 Conclusions 
In this chapter, we demonstrated that particle size strongly affects the ability of gH625 
to deliver PtNPs free in the cytosol, by escaping endo-lysosomes.  
The modulation of peptide functionalization was important to stimulate the efficiency 
of cellular internalization for all the NP sizes, although such effect is significantly 
higher for smaller NPs. Regarding larger PtNPs (5 and 20 nm), we did not find any 
cytosolic localization of the particles, apart from an extremely low fraction (around  
0.5 %) of 5 nm NPs, regardless of gH625 functionalization. On the other hand, for 
particle size of 2.5 nm, we found a population of cytosolic peptide-functionalized NPs, 
where the presence of gH625 elicited a ca. 7-fold fractional increase in cytosolic 
localization with respect to bare particles (the overall gain in cytosolic NPs, promoted 
by the peptide, was thus ca. 80), although single NPs diffusion across cell membrane 
was partly limited by their aggregation in culture medium. Furthermore, the very smal l 
size of gHPt2.5 NPs, combined with the significant enhancement of their cellular 
uptake due to peptide functionalization, showed great advantage in improving the 
antioxidant activity of PtNPs. As matter of fact, these results showed the high potential 
of membranotropic peptides for nanomedicine, as they can provide great benefit to NPs 
in terms of improved delivery and therapeutic action, yet further studies are needed, 
both in vitro and in vivo, to fully understand the size-dependent mechanisms and 
limitations (including the effects of in situ particle agglomeration) of membrane 
penetration and direct cytosolic delivery. 
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Chapter 4  
 
 
Double peptide functionalization 
synergistically enhances PLGA-PEG-NPs 
crossing of the cerebral endothelium 
 
Abstract. The blood-brain barrier (BBB) represents the main obstacle in the treatment of 
Central-Nervous-System (CNS) diseases. It has already been proven that functionalized 
PLGA-PEG NPs with the CRTIGPSVC (CRT) peptide, which functionally mimics the 
endogenous iron, represent a promising brain delivery system due to the high efficacy to 
translocate across the murine BBB, both in static and dynamic conditions. With these 
perspectives, in order to enhance nanocarrier performance, we added gH625 peptide in the 
functionalization setup of NPs. The aim is to investigate the efficacy of this new system in 
promoting the translocation across the cerebral endothelium: co-localization studies, 
adhesion and permeation assays across in vitro brain endothelial model under dynamic 
conditions have been investigated. Results establish that the cooperative effect of CRT and 
gH625 on NPs may change the distribution of NP in the cell and strengthen the BBB 
crossing of NPs. 
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4.1 Introduction 
Brain drug delivery systems have been developed to bypass the blood-brain barrier (BBB) 
in order to therapeutically target central-nervous system (CNS) diseases. To overcome this 
barrier many delivery, strategies have been attempted, such as local injection, induction of 
enhanced permeability.1 Among others, nanotechnologies play an important role in 
developing strategies for brain drug delivery. In the last decades, several methods have 
been designed to overcome or exploit the transport systems of the BBB: non-invasive ones 
involve the systemic application of colloidal drug carriers undergoing a receptor or 
adsorptive mediated transcytosis mechanism.2 In particular, direct targeted delivery of a 
therapeutic cargo to the intended site of action in the brain appears to be one of the most 
promising non-invasive approaches to overcome the BBB.  
By using of nanocarriers, the drug can be transported to the place of action, increasing  
drug concentration in target tissues; in this way, lower doses of drug are required, 
minimizing undesirable side effects to healthy tissues. An ideal nanoparticle (NP) should: 
(i) recognize selectively the targeting tissue, (ii) promote brain drug delivery,  
(iii) have long circulation time, (iv) protect the cargo from enzymatic degradation,  
(v) have low immunogenicity and (vi) have good biocompatibility.3 Usually, NPs enter  
the cell by endocytic pathway: after, endosomes fuse with lysosomes, in which the  
acid environment (pH < 5.5) allows the degradation of the content. As a result, the cargo  
is transferred across the BBB only in few events of transcytosis. For that reason, the design 
of targeted delivery carriers has garnered significant attention in recent years because of 
the potential to achieve highly localized delivery to brain endothelium.4-6 The possibility to 
modulate physical-chemical properties of NPs such as surface charge, size and specific 
functionalization moieties, play an important role in mediating their interactions with cell 
membrane and their intra-cellular fate. 
Therefore, the surface functionalization of nanocarriers with specific ligands such as 
Transferrin (Tf), insulin and low density lipoprotein offers the possibility to recognize and 
cross the BBB endothelium via recognition of specific receptors, overexpressed by the 
cells, and through mechanism of transcytosis. To do so, the use of Receptor-Mediated 
Transcytosis (RMT) systems is considered the most useful strategy that has already  
been proposed for the transport of biologics into the brain.4, 7-8 However, the  
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main limitation of RMT is associated with the low efficiency of BBB crossing  
and the achievement into the CNS. In many cases ligands have high affinity  
only for specific receptors and often this situation is inefficient to promote an  
adequate endocytosis.9 
Researchers have been substantially focusing on identifying new BBB RMT targets. 
Recently, Staquicini et al.10 have identified a new aminoacidic sequence, CRTIGPSVC 
(named CRT), able to recognize selectively brain endothelium and to enhance brain 
crossing of viral particles. Transferrin receptor (TfR) is highly expressed on immature 
erythroid cells, placental tissue and rapidly dividing cells, both normal and malignant. 
Furthermore it is expressed on hepatocytes and endothelial cells of the BBB.11 TfR 
mediates iron delivery to the brain parenchyma via binding and intracellular trafficking of 
the iron-binding protein Tf.12 Internalization of the Tf-TfR complex leads to the endosomal 
compartments in which the acidification allows the release of iron from the ligand. Iron is 
transported into the cytoplasm and is trancytosed, whereas the apo-transferrin (apo-Tf) 
remains tightly bound to its receptor until it reaches the plasma membrane. Here, the apo-
Tf rapidly dissociates from the receptor at neutral pH.13 The free receptor, on the cell 
surface, is available for another cycle of RMT. Staquicini et al. demonstrated in vitro that 
the BBB targeting peptide CRT, mimicking an iron atom, selectively interacts with apo-
transferrin and induce allosteric conformational changes (iron-bound holo-Tf). It finally 
gains access to the brain side, recognizing TfR, through a non-canonical ligand-directed 
mechanism (Figure 4.1). 
 
Figure 4.1. Transcytosis mechanisms of the Fe(III) ion and the iron-mimicking CRT peptide across 
the cerebral endothelium. Reprinted with permission of Ref. 14. 
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To combine targeting and crossing strategies, some research groups developed dual-
functionalized carrier systems for drug delivery across the BBB. For example, these 
systems can be obtained with Transferrin (Tf) and cell-penetrating peptide (CPP) 
functionalization, achieving both target and translocation ability through the BBB.15-16  
The aim of this work is to develop a new PLGA-PEG (PELGA) based nanoparticle able to 
enhance the crossing efficiency through a gH625 and CRT double peptide 
functionalization. Nanoparticles cellular behavior is tested by using an in vitro model of 
BBB, both in static and dynamic condition. 
PELGA based NPs can provide better biocompatibility, higher reproducibility, higher pay-
load properties, easy in functionalization and excellent stability both in vitro and in vivo.17 
In particular, it has been recently reported the versatility of PELGA nanoparticles as 
efficient drug delivery systems.18-22 gH625 is a membranotropic peptide, derived from  
the glycoprotein H (gH) of the Herpes simplex virus type 1. It interacts with model 
membranes, merging with them and is able to traverse the membrane bilayer carrying a 
cargo, like quantum dots, liposomes, NPs and dendrimers into the cytosol and enhance 
BBB crossing.23-24 It has already been demonstrated that gH625-functionalized  
polystyrene NPs facilitate the delivery of nanoparticles across the murine BBB,  
leading to significant higher cell uptake and crossing.25-26 Therefore, we suppose that the 
surface modification of NPs with gH625 may change the classical intracellular  
fate of endocytic pathway, mediating the lysosomal escaping of NPs and enhancing the 
translocation across the BBB. In this work, we synthesized gH625-functionalized  
PELGA-NPs, never reported before in a BBB in vitro analysis. Because of their  
non-specific affinity to different cells, gH625-mediated brain delivery systems could show 
a non-specific distribution in the human body, after systemic administration.  
For this reason, we exploited the ability of CRT peptide to specifically transport  
PELGA-NPs across the in vitro BBB.It has been previously demonstrated that  
CRT-PELGA nanoparticles are able to target and cross the cerebral endothelium. 
Moreover, CRT functionalization enhance uptake, adhesion and crossing ability  
of the particles.27 Consequently, in this work, to overcome the CPP lack of  
targeting specificity, we created a new carrier system, hypothesizing that the coupling  
of gH625 to CRT may enhance NPs transport across the murine cerebral endothelium 
(Figure 4.2). 
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Figure 4.2. Schematic synthesis of dual-functionalized NPs with CRT and gH625 peptides for the active 
targeting and crossing of the cerebral endothelium. 
Dual-functionalized NPs, with 3 different ratios of peptides gH625/CRT (33/66, 50/50 and 
66/33) were synthesized and the effects of the functionalization on the penetration of 
PELGA NP through an in vitro BBB model based on bEnd.3 cell line were investigated.  
In order to evaluate the single contribution of both CRT and gH625 peptides in the  
trans-endothelial ability to cross the in vitro BBB, dual-functionalized NP were compared 
to blank and mono-functionalized nanoparticles: CRT-NPs and gH625-NPs.  
The main outcome of this work is that gH/CRT_33/66 represent the best formulation to 
promote the targeting and crossing through an in vitro BBB under dynamic condition.  
4.2 Experimental section 
4.2.1 Materials 
Equimolar uncapped poly(D,L-lactide-co-glycolide) (PLGA) (Resomer RG502H, average 
Mw 12 kDa) was purchased from Boehringer Ingelheim (Ingelheim, Germany). 
Polyethylene glycol (PEG, Mw 1500 Da), Ethylenediamine (en), N,N-
diisopropylethylamine (DIPEA), O-benzotriazole-N,N,N’,N’-tetramethyluronium-
hexafluoro-phosphate (HBTU), Ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma Pure®), 
anhydrous N,N-dimethyl-formamide (DMF), Acetonitrile (ACN), N,N'-
Diisopropylcarbodiimide (DIC), N,N'-Dicycloexylcarbodiimide (DCC), Rhodamine B, 
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4-(dimethylamino) pyridine (DMAP), Dichloromethane (DCM), Dimethylsulfoxide 
(DMSO), Sodium carbonate (Na2CO3), Piperidine, Trifluoroacetic acid (TFA), Formic 
acid, HPLC-grade water and all buffer solutions were purchased from Sigma-Aldrich 
(USA). All Fmoc-aminoacids were purchased from IRIS Biotech GmbH (Germany). 
Dialysis bag MWCO 6000-8000 Da were purchased from Spectrum Laboratories, Inc. 
(Netherlands). Distilled and deionized water used Millipore Milli-RO 10 Plus (Millipore, 
USA) at 18 MΩ resistance. Amicon® Ultra-4 centrifugal filters were purchased from 
Millipore Merck. 
4.2.2 Synthesis of peptides  
CRT (Ac-CRTIGPSVC-ȕAK-CONH2) and gH625 (Ac-HGLASTLTRWAHYNALIRAFGGG-COOH) 
peptides were synthesized using standard solid-phase-9-fluorenyl methoxy carbonyl 
(Fmoc) procedure and were obtained with good yields (35-40 %). The ȕ-Alanine-Lys (as 
regards CRT peptide) and the Gly3 (for gH625 peptide) residues acted as spacer units 
between polymer and peptide active sequences in order to retain the innate peptide 
conformation when conjugated to the particle surface.  
The syntheses were performed by Biotage Syro Wave peptide synthesizer: Rink Amide 
and Wang resin was used as a solid-phase support for CRT and gH625 peptide, 
respectively. Previously, the C-terminal glycine residue (10 eq) of gH625 peptide was 
manually attached to an equivalent amount of Wang resin using OximaPure® (10 eq),  
DIC (10 eq) and DMAP (0.4 eq). The Fmoc protecting group was removed using 
piperidine 40 % (v/v) solution in DMF. Peptides were cleaved from resin using 
TFA/TIS/H2O (95/2.5/2.5) solution and precipitated in ice-cold diethyl ether. Purified CRT 
peptide was obtain by RP-HPLC starting from 5/95 (v/v) acetonitrile (ACN)/water solution 
containing 0.1 % v/v TFA. For the purification of the gH625 peptide, a 20/80 ACN/water 
solution with 0.1 % v/v TFA was used. Peptides were lyophilized and then characterized 
using ESI-LC-MS. These analyses were carried injecting aqueous solutions of peptides 
into Agilent EclipsePlus C18 RRHD (1.8 µm, 2.1×50 mm) eluted with solvent solution of 
H2O and ACN containing 0.1% v/v of formic acid. A linear gradient of 20-80 % of ACN 
over 8 min at a flow of 150 µl/min was used. 
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MS for CRT peptide: calculated for [M+H]+ = 1176.43 m/z; found (ESI) 
[M+H]+ = 1176.18 m/z, [M+2H]2+ = 588.66 m/z. MS for gH625 peptide: calculated for 
[M+H]+ = 2512.79 m/z; found (ESI) [M+2H]2+ = 1256.68 m/z, [M+3H]3+ = 838.12 m/z, 
[M+4H]4+ = 628.84 m/z. 
Peptide cyclization 
Purified CRT peptide was cyclized by air-oxidation method to allow the formation of the 
intra-chain disulfide bond between the two cysteine residues. Briefly, cysteinyl peptide 
(0.1 mg/mL) was dissolved in 0.1 M sodium carbonate (pH 8) and left to stand open to 
atmosphere under vigorous magnetic stirring until the reaction is complete (48 h).  
The reaction progress was monitored by LC-MS analysis. MS for CRT-cyclized peptide: 
calculated for [M+H]+ = 1174.43 m/z; found (ESI) [M+H]+ = 1173.77 m/z,  
[M+2H]2+ = 587.43 m/z, [M+3H]3+ = 391.97 m/z. Finally, CRT-peptide were purified and 
lyophilized as described above: the product was obtained with 86 % yield. 
4.2.3 Synthesis of copolymers and conjugates 
PELGA 
PLGA-PEG copolymer (namely PELGA) was synthesized via a coupling reaction between 
PLGA and PEG.28 Briefly, the carboxyl group of PLGA were reacted with the terminal 
hydroxyl group of PEG: 1 eq of PLGA, 4 eq of PEG, 0.4 eq DMAP and 2 eq of DCC were 
dissolved in 10 mL of anhydrous DCM. After the reaction (2 days, RT, inert atmosphere), 
the residual DCC was changed into dicyclohexylcarbodiurea (DCU) by adding 10 ȝL of 
bidistilled water. Then DCM was evaporated and the mixture was dissolved in 10 mL of 
DMSO, filtrated and dialyzed (MWCO 6-8 kDa) for 1 day against ACN and for 2 days 
against water. 
The pure product was recovered after lyophilization and its identity was confirmed by  
1H-NMR spectroscopy (600 MHz, CDCl3)μ δ ppm 5.γ0-5.13 (PLGA, CH); 4.92-4.60 
(PLGA, CH2); 3.64 (PEG, CH2); 1.59 (PLGA, CH3). 
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PLGA-amine 
PLGA was functionalized with ethylenediamine (en) which acts as a bridge between 
PLGA and rhodamine (or peptide C-terminus) carboxylic groups. Briefly, 30 mg of PLGA 
502h, 10.3 mg of DCC, 8.7 µl of DIPEA ,10.0 µl of ethylenediamine were dissolved in 
2.5 mL of anhydrous DCM. After the reaction (1 day, RT, inert atmosphere), the residual 
DCC was changed into dicyclohexylcarbodiurea (DCU) by adding 10 µL of bidistilled 
water. Then the solution was filtered and precipitated dropwise into cold methanol, 
centrifuged and then placed under vacuum overnight. 
The identity of pure product was confirmed by 1H-NMR spectroscopy (600 MHz,  
DMSO-d6)μ δ ppm 8.1γ (en, amide); 5.26-5.10 (PLGA, CH); 4.95-4.75 (PLGA, CH2);  
3.14 (en, CH2); 1.44 (PLGA, CH3). 
PLGA-rhodamine 
PLGA-Rhodamine conjugation was performed by a standard coupling procedure: 
PLGA-amine (1 eq), HBTU (5 eq), DIPEA (10 eq) and rhodamine-B (5 eq) reacted in 
anhydrous DMSO for 24 h at RT and then purified by dialysis bags (MWCO 6-8 kDa) 
against water for 3 days. 1H NMR (600 MHz, CDCl3)μ δ ppm 8.4β, 7.85, 7.05 and 
6.92 (rhodamine aromatic proton); 5.30-5.13 (PLGA, CH); 4.92-4.60 (PLGA, CH2);  
4.30, 3.78 (rhodamine CH2); 3.42 (en, CH2); 1.59 (PLGA, CH3). 
PLGA-peptides conjugate 
PLGA-Peptide conjugates were synthesized using a standard HBTU coupling procedure. 
Briefly, for CRT peptide, PLGA (1 eq), HBTU (5 eq), Oxima Pure® (5 eq), DIPEA (10 eq) 
and Peptide (1.5 eq) were dissolved in anhydrous DMSO for 48h at room temperature.  
For gH625 peptide PLGA-amine 2 eq of peptide were used. Adducts were purified from 
unreacted reagents using dialysis bags (MWCO 6-8 kDa) against pure water 
and lyophilized. The reaction products were confirmed by 1H-NMR spectroscopy. 
PLGA-CRT: 1H NMR (600 MHz, DMSO-d6)μ δ ppm 8.50-6.00 (peptide amide backbone); 
5.28-5.14 (PLGA, CH); 4.96-4.84 (PLGA, CH2); 1.47 (PLGA, CH3). PLGA-gH625: 
1H NMR (600 MHz, DMSO-d6)μ δ ppm 8.50-6.00 (peptide amide backbone); 5.28-5.14 
(PLGA, CH); 4.96-4.84 (PLGA, CH2); 3.30 (en, CH2); 1.47 (PLGA, CH3). 
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Nuclear Magnetic Resonance (NMR) analysis 
All Nuclear Magnetic Resonance (NMR) spectra were recorded at 28 °C using an Agilent 
600 MHz (14 T) spectrometer equipped with a DD2 console and an OneNMR HX probe. 
The samples (1 mg) were dissolved in 600 ȝL of λλ.λ% deuterated solvent (Sigma–
Aldrich). 1H 1D spectra were recorded using 256 scans to obtain a good signal-to-noise 
ratio for peptides, en and rhodamine. A saturation PRESAT pulse sequence was used to 
reduce residual peaks of water at 3.33 ppm. Spectra were transformed and analyzed using 
VNMRJ 4 software and chemical shift scale was referenced to the solvent residual  
peak signal. 
4.2.4 NP preparation  
Rhodaminated PELGA-Peptide nanoparticles were prepared by nanoprecipitation 
method.22 In summary, the proper amounts of copolymers and conjugates (Table 4.1) were 
dissolved in acetone and mixed; the final volume was adjusted to 1.3 mL. Afterwards, the 
solution was added dropwise (6 mL/h) with a syringe pump into 12.5 mL of distilled water 
under magnetic stirring (400 rpm). The solution was kept under magnetic stirring until 
complete evaporation of the organic solvent (3-5 h) and the obtained NP suspension was 
sterilized with 0.ββ ȝm membrane filter. Finally, the volume of the solution was reduced to 
1 mL using Amicon® Ultra-4 centrifugal filter. The final NP concentration (mg/mL of 
polymeric species) was estimated by fluorescence intensity measurements of Rhodamine-
PLGA using a spectrofluorometer (Perkin Elmer) that were compared to fluorescence 
intensity of the initial NP concentration before filtration. 
Table 4.1. Mass of copolymers used for blank-NPs, CRT-NPs, gH625-NPs, gH/CRT_33/66-NPs, 
gH/CRT_50/50-NPs and gH/CRT_66/33-NPs preparations. 
NP Sample 
PELGA 
(mg) 
PLGA-Rhod 
(mg) 
PLGA-gH 
(mg) 
PLGA-CRT 
(mg) 
PLGA 
(mg) 
Total 
(mg) 
Blank 1.0 0.4 - - 0.8 2.2 
CRT 1.0 0.4 - 0.4 0.4 2.2 
gH625 1.0 0.4 0.4 - 0.4 2.2 
gH/CRT_33/66 1.0 0.4 0.2 0.4 0.2 2.2 
gH/CRT_50/50 1.0 0.4 0.4 0.4 - 2.2 
gH/CRT_66/33 1.0 0.4 0.4 0.2 0.2 2.2 
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4.2.5 NP characterization  
Mean size, size distribution and ζ-potential of NPs were determined by dynamic light 
scattering (DLS) measurements (Zetasizer Nano ZS, Malvern Instruments, UK) on a  
0.1 mg/mL water suspension of each kind of NPs (Table 4.1).  
4.2.6 Cell culture  
Immortalized mouse cerebral endothelial cells, (bEnd.3; American Type Culture 
Collection, Manassas, VA) were grown in DMEM with 4.5 g/L glucose, 10 % Fetal 
Bovine Serum (FBS), 3.7 g/L sodium bicarbonate, 4 mM glutamine, 1 % non-essential 
amino acids, 100 U/mL penicillin and 0.1 mg/mL streptomycin in 100 mm diameter cell 
culture dish, in a humidified atmosphere at 37 °C and 5 % CO2. Cells used in all 
experiments were at passage 22-30.  
4.2.7 Co-localization studies  
Indirect immunofluorescence against endocytic markers may give information about the 
endocytic mechanisms underlying nanoparticle cellular uptake. The co-localization 
experiments were carried out on 70% confluent cells seeded on glass coverslips. 
All the reagents and solutions were prepared as follows. For co-localization experiments 
with lysosomes, about 1×104 bEnd.3 were seeded on the round 12 mm-diameter glass 
coverslips placed in 24 well plates. Cells were incubated for 24 h with all kind of NPs 
made. After, bEnd.3 were first rinsed twice with PBS to remove non-internalized NPs and 
fixed with 400 ȝL of 4% paraformaldehyde at room for 10 min. For lysosomes staining, 
cells fixed were permeabilized with 0.05% saponin-PBS for 10 min and incubated with 
FBS-PBS 10% for 20 min at room temperature to block unspecific sites. Lysosomes were 
localized with rabbit 1:150 anti-LAMP-2 polyclonal (Abcam, 1 mg/mL) primary antibody 
for 1 hour at room temperature in a humidified chamber and with 1:200 AlexaFluor 488 
anti-rabbit secondary (1 ȝg/mL) antibody for γ0 min. After mounted the coverslips on 
glass slides with PBS/glycerol (1:1) solution, immunofluorescence analyses were 
performed by means of confocal laser scanning microscope. 
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4.2.8 Permeability assay to NPs in Transwell system 
bEnd.3 were seeded at a density of 3×104 cells/cm2 on Transwell permeable inserts 
(6.5mm diameter, γ ȝm pores size; Corning Incorporated, Corning, NY). Permeability 
experiments were performed after 7 days from the seeding, allowing sufficient time for the 
cells to develop the junctions between cells. On the day of experiment, Transwell insert 
filter was washed with PBS and then the media of the donor chamber was filled with 
150 ȝL cell culture medium w/o phenol red containing 0.1 mg/mL of all NPs samples, 
while the acceptor chamber was filled with 400 ȝL cell culture medium without  
phenol red. The samples of 400 ȝL were drawn every γ0 min for β h from the acceptor 
chamber and were then replaced with the same amount of fresh medium. 
The fluorescence tracer concentration in the samples was determined by a 
spectrofluorometer (Victor, Wallac, PerkinElmer) with excitation and emission 
wavelengths of 557 and 578 nm, respectively. The permeability (P) to NPs of the bEnd.3 
monolayer was calculated according to the following equation: 
ܲ =  ∆��∆� × �ܸ�஽ × �  
Where ΔCA is the increase in fluorescence concentration in the acceptor chamber  
during the time interval Δt, CD is the fluorescence concentration in the donor chamber 
(assumed to be constant during the experiment), VA is the volume of the acceptor  
chamber and S is the surface area of the filter.29 The experiments were performed in 
triplicate. 
4.2.9 NP adhesion assay to BBB by using Glycotech system 
To perform NP adhesion assays, 4×105 bEnd.3 were seeded on round glasses (Ø = 60 mm) 
placed in Petri dishes (Ø = 100 mm). The experiments were performed after 3 days from 
the seeding. Adhesion assay to an in vitro model of BBB grown on the glass coverslip was 
performed by using Glycotech system. The system consists of a PMMA flow deck with 
inlet and outlet bores, a silicon gasket and a glass coverslip (Figure 4.3). The silicon gasket 
separates the acrylic flow deck and the glass and defines the flow area.  
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are shown in Table 4.2. Data indicate that the particle used for all the experiments are 
almost of the same size, narrowly distributed and substantially different in surface charge 
with respect of the functionalization. In particular, less negative charges were shown with 
the increase of gH625 surface fraction; this trend is probably due to the net positive charge 
of the protonated amino-acid side chains at physiological condition. 
Table 4.2. Size, polydispersity and ζ-potential measurements of PELGA-NPs at each functionalization degrees. 
NPs Samples 
Size 
(Ø, nm) 
PDI 
ζ-Potential 
(mV) 
Blank 88 ± 2 0.15 -27.4 ± 0.7 
CRT 92 ± 2 0.15 -26 ± 1 
gH625 84.5 ± 0.8 0.14 -13.8 ± 0.2 
gH/CRT_33/66 76.7 ± 0.9 0.13 -22.1 ± 0.5 
gH/CRT_50/50 78 ± 1 0.14 -20.8 ± 0.6 
gH/CRT_66/33 84.1 ± 0.7 0.14 -19.4 ± 0.7 
4.3.3 Co-localization studies  
To further investigate the fate of NPs, intracellular distribution and co-localization 
experiments within endocytic compartments (lysosomes) were carried out. After 24 h  
of incubation, the samples were fixed with paraformaldehyde 4 % for 10 min and observed 
by confocal microscope after lysosomes staining with LAMP-2. As shown in Figure 4.5, 
all kind of nanoparticles are internalized by the cells and display different intracellular 
localizations. Blank-NPs and CRT-NPs are distributed as spots mainly localized  
in the perinuclear region of the cell and are partially co-localized with lysosomes.  
On the other hand, gH625-NPs have a more cytoplasmic distribution with no significant 
lysosomes co-localization. Furthermore, localization of dual-functionalized NPs  
changes as a function of the formulation, since lysosomal or cytoplasmic distribution  
is increasing with the CRT or gH625 amount, respectively. 
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Figure 4.5. Colocalization of blank-NPs (A,D), CRT-NPs (B,E), gH625-NPs (C,F), gH/CRT_33/66-NPs (G,J), 
gH/CRT_50/50-NPs (H,K) and gH/CRT_66/33-NPs (I,L) with lysosomes after 24 h incubation in bEnd.3 cells. 
Red: NPs; green: LAMP-β. Scale bar 50 ȝm. 
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in assisting the trans-endothelial crossing, in particular for lower gH625/CRT peptide ratio. 
Thus, gH/CRT_33/66-NPs have the highest value for trans-endothelial crossing ability. 
 
Figure 4.7. Permeability of bEnd.3 cell monolayer to blank, CRT, gH625, gH/CRT_33/66, 
gH/CRT_50/50 and gH/CRT_66/33 functionalized NPs. 
Burdo et al.33 demonstrated that iron is transported across endothelial cells both bound 
to Tf (holo-transferrin) and not bound to Tf (apo-transferrin). Several works reported 
that after endocytosis in brain endothelium, the complex Tf-TfR-iron is transported in 
coated vesicles to lysosomes, in which the presence of the iron chelating component 
desferrioxamine removes the iron from the complex. Then, the iron is transported 
across the membrane of the vesicle into the cytoplasm and is transcytosed, by still 
unclear mechanism. Fisher et al.34 identified iron transport proteins such as ferritin for 
iron transcytosis, Mc Carthy et al. identified ferroportin.35 On the other hand,  
apoTf-receptor complex is sorted into recycling endosomes to the blood on the luminal 
membrane.36-37 
Co-localization studies according with NP transport results, suggest that after the 
internalization, the complex CRT iron mimicking peptide-Tf-TfR is transported  
to lysosomes at pH 5-5.5 and then CRT-NP is removed from Tf/TfR complex.  
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At that point, CRT-NP is transported into the basal compartment separately. On the 
contrary, the cytoplasmic distribution of gH625-NPs is probably due to the working 
mechanism of gH625 peptide that promotes lipid membrane-reorganizing processes, 
through fusion, involving temporary destabilization and subsequent reorganization of 
the membrane.23 However, no significant crossing ability was observed when gH625 
was exposed on PELGA-NP. Probably, peptide on NP is not able to assume the correct 
conformation and thus it is able to recognize lipid membrane of cells but does not exert 
its activity. 
4.3.5 Adhesion assay in flow condition 
Parallel plate flow chamber Glycotech system is a commercial device that mimics the 
hydrodynamic conditions at microcirculation level. This assay were performed in order 
to investigate in what way the surface functionalization could affects the in vitro 
targeting ability of the NPs to a cerebral endothelium under flow conditions.  
The volumetric flow rate Q (10 ȝL/min) was fixed to be equal for all the experiments. 
Based on this and on the other structural parameters (�, ℎ), we calculated the  
mean velocity within the chamber (ܷ = ܳ/�ℎ = 0.066 mm/s), the shear rate  
(� = 6ܳ/ℎ2� = 1.55 s-1) and the shear stress at the wall (�� = μ � = 1.86×10-3 Pa).  
The mean velocity used for the experiments was comparable with the blood velocity  
in the human capillary vessel (between 0.01 and 0.1 mm/s)38 and the shear rate and stress 
values at the wall were sufficiently small to allow adhesion of nanoparticles  
to endothelial cells.39 
Among dual functionalized NP formulations, gH/CRT_33/66-NPs have the highest of 
trans-endothelial crossing ability and were chosen to assess whether these NPs could 
adhere to the BBB also under dynamic conditions. Confocal images for each NP type 
were acquired and analyzed by imageJ software. Figure 4.8 compares the adhesion 
ability (Figure 4.8 A) and localization (Figure 4.8 B-I) of blank-NPs, CRT-NPs, gH625-
NPs and gH/CRT_33/66-NPs. Data are reported as the percentage of mean gray value. 
As shown, CRT-NPs and gH/CRT_33/66-NPs display the highest targeting ability at 
10 ȝL/min flow rate (0.7λ % and 0.λ7 %, respectively) compared to blank-NPs (0.44 %). 
Percentage of mean gray value for gH625-NP was found equal to 0.60 %.  
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Figure 4.8. (A) NP adhesion ability to bEnd.3 under flow condition, ܳ = 10 ȝL/min. P *= < 0.05; 
P **= < 0.005. (B-I) confocal images of NPs in bEnd.3 after the experiments: (B,F) blank-NPs, 
(C,G) CRT-NPs, (D,H) gH625-NPs and (E,I) gH/CRT_33/66-NPs. Red: NPs; blue: nuclei. Bar 50 ȝm. 
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4.4 Conclusions  
The aim of this work was to characterize the effect of functionalization of 
biodegradable nanoparticles with two synthetic peptides in enhancing targeting and 
transport across the cerebral endothelium. Sub-100nm PELGA NPs were successfully 
synthesized with three different ratios of CRT and gH625 peptides by using 
nanoprecipitation method. Results clearly indicate that NPs are internalized by the 
cells. NPs also show different intracellular localization, strongly guided by peptide 
functionalization. As a matter of fact, gH625 lead the NPs to a more cytoplasmic 
distribution while CRT peptide induces lysosomal accumulation. Similar behavior is 
shown also for blank NPs. NPs transport results in Transwell system demonstrated that 
the permeability of the cerebral endothelium to gH/CRT_33/66 and CRT-NPs is about 
2.5 and 1.5 times higher than blank NPs, respectively. Further investigations about NPs 
targeting ability in flow condition were performed using Glycotech system assays.  
The experiments were carried out using a flow rate of 10 ȝL/min in order to simulate 
the blood velocity in human capillaries. Data reported as the percentage of mean gray 
value indicates that gH/CRT_33/66 formulation has the highest targeting ability to the 
BBB under flow conditions. More precisely, the percentage of gH/CRT_33/66 and 
CRT-NPs is about 2.2 and 1.8 times higher than blank NPs, respectively.  
No significant adhesion ability was found for gH625-NPs and this can be ascribed to 
the lacks of specificity to the BBB of gH625. Taken all together, these findings 
demonstrated a cooperative effect of gH625 and CRT peptides when exposed on dual 
functionalized NPs in percentage 33/66, respectively. Probably peptides in 
gH/CRT_33/66-NPs formulation are able to assume the correct conformation and to 
exert their activity, promoting NP transport across the BBB in a synergic manner.  
The new nanocarrier, made up of FDA-approved materials, could be regarded as a 
promising strategy for administration of therapeutical compounds to the brain.  
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Chapter 5  
 
 
Conclusions and future prospective 
 
 
 
The work described in this thesis intends to exploit the remarkable properties and 
applications of gH625 cell-penetrating peptide. 
Up to now, cell-penetrating peptides have been widely used in improving cellular 
translocation of covalently or electrostatic attached cargoes. Based on the scientific reports 
in the literature, it seems that the CPPs are finally starting to catch up with the alternative 
non-viral systems, as more efficient and comprehensive applications are described.  
It has become increasingly clear that CPPs translocate the cell membrane through different 
mechanism, which depends on the CPP itself but, in principal, on the cargo  
physico-chemical nature. More important is that endosomal entrapment represents the 
major bottleneck in many cellular delivery methodologies, including CPP-mediated 
delivery. Despite many studies, mechanisms responsible for the extravasation and for the 
cellular trafficking of these CPP–drug conjugates or complexes are still poorly understood. 
Overcome these limitations will obviously help in engineering of new CPP generations 
with a superior potential to target various tissues and to deliver their payload within the 
appropriate cellular compartment. 
For this purpose, our study was definitely pointed in those directions, exploring new 
targeting and delivery applications of gH625 CPP and evaluating its behavior as 
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engineering transport agent. In more details, in Chapter 1 an introduction to the topic is 
given. In Chapter 2, it is shown how CPP functionalization and reverse transfection 
approach leads to a highly efficient vector transport for intracellular delivery of nucleic 
acids. Results demonstrate that the PEI/gH625 construct successfully achieve an increase 
of the transfection efficiency of non-viral polymeric carriers. Furthermore, we were able to 
reduce their own cytotoxicity and mediate an efficient gene transfer with respect to un-
functionalized vectors. Despite of the unsuccessful covalent approach, we effectively 
developed a facile and clear method for the building up of modified PEI vector and 
functionalized glass substrate. 
In Chapter 3, we analyze the behavior in cell culture of gH625 functionalized PtNPs of 
different size (2.5, 5 and 20 nm). The presence of the CPP significantly increased the 
amount of internalized NPs in human cervix epithelioid carcinoma cells, as a function of 
particle size. However, scanning transmission electron microscopy (STEM) and electron 
tomography (ET) revealed a predominant confinement of PtNPs within vesicular 
structures, regardless of particle size and surface functionalization. Only in the case of the 
smallest 2.5 nm particles, the membranotropic peptide was able to partly maintain its 
functionality, enabling cytosolic delivery of a small fraction of internalized PtNPs.  
Single-particle transport across the cell membrane is strongly hampered by particle 
agglomeration in culture medium. Interestingly, membrane crossing seemed to occur by 
diffusion through the lipid bilayer, with no apparent membrane damage. For larger particle 
sizes (≥5 nm), their hindrance likely blocked the membranotropic mechanism. Combining 
the enhanced uptake and partial cytosolic delivery promoted by gH625, we were able to 
achieve a strong improvement of the antioxidant nanozyme function of 2.5 nm PtNPs, 
decreasing both the endogenous ROS level and its overproduction following an external 
oxidative insult. 
So far, it has been shown that various types of cargo have been effectively transported 
through biological barriers, providing most diverse ways of interfering with the cellular 
biochemical processes. Nevertheless, it is a challenge to target the delivery only to  
specific cells, tissues or organs. Fusions of various approaches allow combining  
both active and passive targeting and achieve potentially higher selectivity and efficacy.  
As a matter of fact, in Chapter 4, gH625 was conjugated to PLGA-PEG NPs together with 
CRT peptide, which functionally mimics the endogenous iron and promotes the BBB 
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crossing through recognition of the transferrin receptors of the cerebral endothelium.  
Co-localization studies, adhesion and permeation assays across in vitro brain endothelial 
model under static and dynamic conditions have been investigated. Results establish that 
the cooperative effect of CRT and gH625 on NPs changes the distribution of NP in the 
cell, avoiding nanoparticle accumulation inside lysosomal compartments and support the 
translocation across the blood-brain barrier. 
To sum up, in this thesis is shown the key role of the gH625 membranotropic peptide in 
the construction of novel materials, increasing their capability in the overcome of 
biological barrier. In this way it was possible to prepare functionalized polyplexes, 
platinum and PLGA NPs, with less cytotoxic effects and higher transfection, antioxidant 
and brain targeting and delivery performance, respectively. Overall, this work shows the 
high potential of gH625-based delivery agents for nanomedicine, providing optimism for a 
wide range of further therapeutic applications. 
 
